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Introduction: Alcohol use disorder remains one of the major health problems worldwide, 
causing excess morbidity and mortality. Alcoholic liver disease constitutes one of the major 
components of alcohol-associated morbidity, and alcoholic cirrhosis is the leading cause of 
alcohol-related death. In the course of alcoholic liver disease, alterations in bile acid 
metabolism play a critical role, leading to impaired bile secretion and the formation of 
hepatotoxic mediators. Two members of the endocrine subfamily of fibroblast growth factors, 
FGF21 and FGF15/19, are reported to regulate bile acid biosynthesis, but only sparse data 
exist hitherto about their exact functions in the setting of alcohol intake and/or alcoholic liver 
disease. 
Patients and methods: Wild-type (C57BL/6J) and Abcb4 knockout mice (which develop a 
cholestatic liver disease mimicking primary sclerosing cholangitis) were fed with either 
ethanol containing or control diet (using the preestablished NIAAA - National Institute on 
Alcohol Abuse and Alcoholism - protocol). Tissue expression and circulating levels of FGF21 
and FGF15 were measured in both groups and mouse types. Serum bile acids and mRNA 
expression of the major enzymes of bile acid metabolism were determined. Liver specimens 
were histologically examined for cholestatic damage. Furthermore, recombinant human 
FGF21 was added to primary murine hepatocytes in order to assess the direct effect of 
FGF21 on the expression of CYP7A1, which encodes the rate-limiting enzyme of hepatic bile 
acid synthesis. Subsequently, serum levels of FGF21 and FGF19 and oxysterols were 
determined in patients with alcoholic liver disease and ongoing ethanol consumption and 
compared to a cohort of healthy control subjects, in order to translate the experimental 
findings to humans. 
Results: Ethanol consumption consistently upregulated hepatic and circulating levels of 
FGF21 in both humans and rodents. The observed upregulation was preserved even in the 
context of preexisting cholestatic liver disease (in rodents) or alcoholic liver disease (in 
humans). The upregulation of FGF21 elicits in vivo and in vitro a suppression of CYP7A1. 
The suppression took place in a dose-dependent manner and appeared to be independent of 
FGF15/19 signaling. 
Conclusions: Ethanol intake induces increased hepatic expression and circulating levels of 




This action is retained even in the setting of preexisting liver disease and presents a potential 




























Einleitung: Alkoholabusus stellt unverändert ein erhebliches Gesundheitsproblem dar und 
führt zur exzessiven Morbidität und Mortalität. Die alkoholische Fettlebererkrankung und 
Steatohepatitis sind zentrale Komponenten der alkohol-assoziierten Morbidität, und die 
alkoholische Leberzirrhose ist die führende alkohol-assoziierte Letalitätsursache. Im Verlauf 
der alkoholischen Lebererkrankung spielen Veränderungen des Stoffwechsels der 
Gallensäuren, die zu gestörten Exkretion in die Galle und Überproduktion von 
hepatotoxischen Molekülen führt, eine wichtige Rolle. Zwei Mitglieder der Familie der 
endokrinen Fibroblast Growth Factors, FGF21 und FGF15/19, sind an der Regulation der 
Synthese der Gallensäuren in der Leber beteiligt. Aktuell sind nur wenige Daten über ihre 
Effekte im Rahmen der alkoholischen Lebererkrankung verfügbar. 
Patienten und Methodik: Die Mausinzuchtlinie C57BL/6J und Abcb4 Knockout-Mäuse (die, 
eine cholestatische Lebererkrankung, ähnlich zur primär sklerosierenden Cholangitis, 
entwickeln) wurden entweder mit Kontrolldiät oder einer alkoholischen Diät ernährt, gemäß 
dem vorher etablierten NIAAA Protokoll. Gewebeexpression und Serumkonzentrationen von 
FGF21 und FGF15 wurden in allen Gruppen bestimmt. Die mRNA Expression der 
wichtigsten Enyzme der biosynthetischen Kaskade der Gallensäuren wurden ebenso 
bestimmt. Die Lebergeweben wurden histologisch nach cholestatischer Schädigung 
untersucht. Primäre Hepatozyten wurden mit reombinantem humanen FGF21 inkubiert , um 
dessen Einfluss auf die hepatische Expression von CYP7A1, dem 
geschwindigkeitslimitierenden Enyzm der Gallensäurensynthese, zu untersuchen. 
Anschließend wurden die Serum-Spiegel von FGF21, FGF19 und Oxysterolen bei Patienten 
mit alkoholischer Lebererkrankung und fortgesetztem Alkoholabusus und einer 
Kontrollgruppe von gesunden Probanden bestimmt. 
Ergebnisse: Alkohoeinnahme führte zur Erhöhung der hepatischen Produktion und des 
Serumspiegels von FGF21, sowohl in den Tiermodellen als auch bei den Probanden. Diese 
Erhöhung blieb auch im Rahmen einer vorbestehenden cholestatischen Leberschädigung (in 
den Mäusen) oder der alkoholischen Lebererkrankung (bei Patienten) erhalten. Die erhöhte 
Produktion von FGF21 führte zu einer dosisabhängigen Suppression von CYP7A1, sowohl in 
vivo als auch in vitro. Diese Suppression erfolgte in einer nicht FGF15/19 vermittelten Weise. 
Schlussfolgerungen: Ethanol induziert die Synthese von und erhöhte die systemischen 
Spiegel von FGF21. Das hochregulierte FGF21 supprimiert die Biosynthese der 




































Alcohol abuse remains as one of the main causes of excess morbidity and mortality worldwide 
and has been further associated with social, emotional and economic consequences not only 
for the patient himself but for his complete environment (112). The disease burden caused by 
excessive alcohol intake makes it attractive to reveal the underlying pathomechanisms, which 
induce or retain alcohol use disorder. One of the major and most prevalent pathological 
conditions associated with excessive alcohol ingestion is the alcoholic liver disease (ALD) that 
appears to be the most prevalent type of chronic liver disease worldwide (112). However, an 
effective treatment currently does not exist for ALD, except the application of corticosteroids 
for acute alcoholic steatohepatitis treatment, which has been suggested in the 1970s, or liver 
transplantation in the final stages of the disease (120). Therefore, there is further need to 
discover potential pharmacological targets, in order to restrict alcohol use disorder or unveil 
innovative treatments for its detrimental effects on vital organs such as liver or heart. 
Alcoholic liver disease is a progressive disease, with a wide spectrum of liver disorders ranging 
from hepatic inflammation (called steatohepatitis) and impaired or changed bile acids synthesis 
to more severe liver defects such as cirrhosis and hepatocellular carcinoma (HCC) (120). The 
causative pathomechanism of ALD is complicated and not yet fully understood and 
encompasses hepatic fat accumulation, oxidative stress and cytokine and chemokine induced 
inflammation (120). Since the emerging evidences demonstrate a pivotal role of the altered 
bile acids (BA) metabolism in the pathogenesis and physical course of ALD (46,148,157,158), 
exposing the underlying mechanisms could lead to potential therapeutic manipulations. In this 
context, the emerging roles of the two members of the endocrine fibroblast growth factors 
(FGF) family, the FGF21 and FGF19 (the human orthologue of FGF15 in mice) have been 
supported as intriguing targets of acute liver damage (29). It has been supported that FGF19 
is predominantly produced in ileum postprandially and suppresses bile acid synthesis as an 
important part of glucose and lipid homeostasis, whereas, FGF21 is a key metabolic regulator 
acting as a hepatokine and primarily enorchestrating the adaptative response to starvation 
(29). As far as the alcohol use disorder is concerned, there is evidence from previous studies 
that acute ethanol ingestion upregulates both the hepatic expression and serum concentration 
levels of FGF21 in previously healthy humans and in mice (27,128). It has been supported that 
this upregulation aims to ameliorate the devastating metabolic changes caused by alcohol 
intake and trigger the fat accumulation and inflammation in liver (27,128). Moreover, increased 




comprises a part of a liver-brain axis that regulates the gustatory preference for ethanol and 
sugar (27,128).  
The main aim of the present study is the examination of the exact role of chronic plus binge 
alcohol induced FGF21 on bile acid metabolism by using a recently established acute on 
chronic liver injury (ACLI) mouse model with a preexisting chronic cholestatic liver injury (61). 
In order to obtain a pattern of a cholestatic liver damage, ATP binding cassette subfamily B 
member 4 gene knock out (Abcb4−/−) mice have been used. These mice lack the canalicular 
phospholipid flippase, which leads to decreased ability for secretion of phospholipid into bile 
(9,108) causing a type of spontaneous biliary fibrosis (108). Recent studies showed a novel 
suppressive effect of FGF21 on bile acids synthesis rate limiting enzyme, cholesterol 7 alpha-
hydroxylase (CYP7A1), which was known to be inhibited through FGF19 in liver as a negative 
feedback of bile acid synthesis regulatory mechanism (17,74).  
In the current study, the impact of alcohol induced FGF21 on bile acids metabolism has been 
investigated in mice and human. The importance of the study was to observe FGF21 response 
mechanism and its relation to hepatic bile acid homeostasis, which is described for the first 
time in an alcohol related acute-on-chronic liver injury model. 
 
1.1 PREVALENCE, PATHOPHYSIOLOGY, COMPLICATIONS AND 
THERAPY OF ALCOHOLIC LIVER DISEASE 
 
The alcohol use disorder is defined as an aberrant model of habitual ethanol consumption, 
leading to clinically recognized significant distress and impairment of health quality, identified 
by the diagnostic criteria set by the diagnostic and statistical manual of mental disorders, 5th 
edition (DSM-5) (at least two within 1 year)  (Table 1) (28). 
A pathological pattern of ethanol consumption has been found to be correlated with an increase 
in the disease burden and mortality (156). Data from the World Health Organization (WHO) 
indicate that ethanol consumption and especially alcohol use disorder are associated with 
elevated risk of infectious, cardiovascular, malignant, metabolic, neurologic, hepatic, traumatic, 
reproductive, maternal, newborn/child/adolescent and psychiatric diseases and are linked to a 
further hazardous behavioral pattern (unprotected sex, dangerous driving, aggressive and 






Table 1: Diagnostic Criteria of Alcohol Use Disorder. The fifth edition of Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) criteria for the framing of patients with alcohol use disorder (AUD) 
(28).  
 
Alcoholic liver disease remains currently the dominant liver disease in Europe and the United 
States (11,104,112). In 2010, ALD represented 10.4% of all alcohol-attributable deaths 
worldwide and 47.9% of all deaths attributable to liver cirrhosis were because of alcohol intake 
(112). However, the exact prevalence of ALD might be underestimated since many patients 
with mild symptoms or within the earliest phase of the disease were not registered. The 
relationship between alcohol consumption and liver associated mortality has already been 
suggested in 1967 by Terris M et al., who found out an association between decreased rates 
of liver cirrhosis and decreased levels of alcohol intake especially during historical events, such 
as the world wars (140). Subsequently, this suggestion has been proved by WHO, indicating 
a positive correlation between amount of reported alcohol intake and prevalence of alcoholic 
liver disease in European areas (11,156). The ongoing chronic alcohol consumption may 
increase the risk of alcoholic fatty liver disease, even if the consumed amount is in the 
permitted threshold. A significant risk of ALD rises with alcohol consuming above this 
threshold, which is also very difficult to define because of the multifactorial nature and the 
diverse stages of this manifestation (111) (Figure 1). The exact risk estimation becomes more 
challenging in the context of binge abuse, where a precise quantification is practically 




pathophysiological events with corresponding clinical manifestations could be recognized as 
depicted in Figure 1. 
 
 
Figure 1: The typical physical course of disease progression in ALD from fatty liver disease to 
established liver cirrhosis with elevated risk of HCC. There are diverse factors that can unpredictably 
modify the time course or severity of each manifestation. Adapted from Nature Reviews/Disease Primers 
(120). 
 
The state of steatohepatitis is characterized by the presence of an active inflammation in 
addition to alcoholic fatty liver with a percentage of 10-35% as it is shown in Figure 1. It has 
been supported that the existence of inflammation is an essential precondition for the structural 
alterations, which are typical for the disease hallmarks of liver fibrosis or cirrhosis (120). The 
evolvement of the disease from a pro-inflammatory situation to a function-relevant destruction 
comprises a cascade of events, which eventually starts with gut-derived pathogen-associated 
molecular patterns (PAMPs), suggesting that the gut microbiota and the gut-liver axis have 
crucial roles for the fueling of the inflammatory sequel (120). The pivotal consequence is finally 
the secretion of inflammatory cytokines from the Kupffer cells, which are one of the most 
important part of the mononuclear phagocyte system. This is ultimately leading to the release 




follows the stimulation of receptors, which are expressed not only by immunoactive cells, but 
also by the hepatocytes themselves, such as the Toll-like receptors (TLRs) and NOD-like 
receptors (NLRs) (57,58,103,107).   
An inflammation induced hepatocellular damage is the prerequisite for fibrogenesis, which can 
be considered as a maladaptive healing response to liver injury that results in altered 
parenchymal structure and pericellular and perisinusoidal matrix accumulation (120). These 
pathologic changes affect only a fraction of the patients that have developed inflammatory 
steatohepatitis. However, the predisposing factors of inflammatory steatohepatitis and their 
exact impacts are not fully elucidated yet. An initial event seems to be the hyperactivation of 
hepatic stellate cells (HSCs) that can be induced by previously activated Kupffer cells 
(32,45,66,98), reactive oxygen species (ROS) produced by the changes in oxidative/reductive 
potential, direct activation of alcohol and its metabolites, and through the endoplasmic 
reticulum stress (120). Indeed, a proinflammatory state is favored by means of inhibition of 
anti-inflammatory agents and the fibrogenetic processes, such as activation of natural killers 
(NK) and production of interferon γ (IFNγ), which cause the apoptotic cell death of the activated 
HSCs (59,110). The main process of the fibrogenesis is the uncontrolled proliferation and 
activation of the HSCs and the excessive production of extracellular matrix, which destructs 
the parenchymal architecture of the liver. As the fibrosis progresses, the liver becomes cirrhotic 
and impaired blood flow in the hepatic vessels, biosynthetic dysfunction and predisposition to 
cholestasis take place (59,110,120).  
The final stage of ALD is the progression of the disease to liver fibrosis, cirrhosis and 
subsequently to hepatocellular carcinoma (HCC), which is the most relevant issue in the 
clinical praxis. The elevated risk of HCC with the progression of advanced fibrosis or cirrhosis 
has been suggested to be dependent on alcohol intake and subsequently occurred functional 
and structural changes caused by fibrogenesis (7). Alcohol is considered to be carcinogenic 
because of its metabolite acetaldehyde, which is the primary carcinogenic substance (7). 
Acetaldehyde acts directly on DNA in a mutagenic way, inhibiting its self-repairing capacity 
through inactivation of the enzyme O6-methylguanine DNA methyltransferase (83,142,155). 
Further predisposing factors, which are associated indirectly with alcohol consumption and 
linked to fibrogenesis, are the release of ROS, which induce the production of carcinogenic 
metabolites that activate preexisting procarcinogens, such as nitrosamines, and methylation 
alterations causing epigenetic chromosomal instability (44,147,150). The pathophysiological 
cascade of ALD progression from excessive alcohol consumption to cirrhosis with increased 




There are numerous risk factors, which affect the vulnerability of ALD development or its 
clinical complications individually. Among these risk factors, genetic susceptibility is also 
strongly assumed with the data indicating an association between genetic proneness and 
alcohol consumption and ALD development (133). This fact partly explains why only a fraction 
of human population has an established disease susceptibility following alcohol abuse. In this 
regard, patatin like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 
superfamily member 2 (TM6SF2) and membrane-bound O acetyltransferase domain-
containing protein 7 (MBOAT7) genes have been considered to be crucial for the development 
and severity of ALD (12,115,132).  The induction of a proinflammatory and fibrogenetic state 
enables the gradual progression of the disease. It is subsequently appealing to assume, that 
genetic alterations concerning the production of cytokines or chemokines and the inflammatory 
responsiveness could have a pivotal role as determinants for the severity of alcohol induced 
disease.  
The diagnosis of ALD requires biochemical, sonographic and histopathological evidence of 
liver disease in addition to a significant alcohol use disorder (AUD) state. However, the 
detection of AUD is difficult in the clinical praxis since the amount of ethanol consumption or 
time of consuming is in most cases impossible to be objectified or quantified. In addition, the 
measurement of alcohol metabolites in plasma or urine is not common in the clinical routine, 
with the exception of several groups, i.e. the patients on a transplantation list. Biochemical 
markers, such as elevated transaminases, bilirubin, alkaline phosphatase and γ 
glutamyltransferase, biomarkers of reduced biosynthetic capacity, such as low albumin or 
elevated international normalized ratio (INR), the sonographic liver pattern (echogenicity and 
homogenicity of the parenchyma, tumours, cholestasis, and structural deformation) and the 
result from transient elastography can together be confirmed with the clinical evaluation to 
stage ALD. Specifically during a transient elastography, the control attenuation parameter 
(quantifiable in the context of attenuation of shear waves) has a high diagnostic accuracy 
especially for severe hepatic steatosis, although it could not appropriately distinguish its cause 
(30,56,143). The measured liver stiffness can diagnose cirrhosis in a non-interventional way 
showing sufficient correlation with the histological stage of fibrosis (89). The cutoff values for 
staging liver fibrosis are shown in Figure 3 in the setting of an acute liver disease. In this 
context, it remains disputable if the diagnosis should be histopathologically confirmed via liver 







Figure 2: Pathomechanisms linked to induction of alcoholic liver diesease and progression from fatty 
liver to cirrhosis with elevated risk of carcinogenesis. ROS: reactive oxygen species, ADH: alcohol 
dehydrogenase, NAD: nicotinamide adenine dinucleotide, ALDH: aldehyde dehydrogenase, εdA: 1,N6 
-etheno-2′-deoxyadenosine, M1dG: 3-(2-deoxy-β-d-erythro-pentofuranosyl)pyrimido(1,2-α)purin-
10(3H)-one, 4-HNE:  4-hydroxynonenal, MDA: malondialdehyde. Adapted from Nature 
Reviews/Disease Primers (120) 
 
The milestone of ALD management is alcohol cessation, which is challenging and necessitate 
the interdisciplinary collaboration especially between hepatologists and psychiatrists. A 
combination of psychological and pharmacological treatment can be proved contra-intuitively 
very effective with long time maintenance of the succeeded result. The abstinence therapy 
needs in some cases hospitalization and hepatological follow up (1,5,127).  
In the state of alcoholic steatohepatitis supportive care is recommended such as albumin 




administered in the case of an acute alcoholic hepatitis (125,145). On the other hand, 
additional administration of pentoxifylline did not offer any additional advantage (82). On the 
contrary, N-acetyl cysteine administered with corticosteroid has been shown to be effective in 
improvement of liver function (94). Liver transplantation remains to be ultimate treatment 
modality for patients with severe cirrhosis or hepatic malignancy and should be evaluated 





Figure 3: Algorithm for clinical interpretation of liver stiffness in ALD. AST (Aspartate Transaminase) 
adapted cut-off values for liver stiffness for staging of fibrosis. These values can differ in liver fibrosis of 





1.2 THE ROLE OF FGF21 IN ALCOHOLIC LIVER DISEASE 
 
Fibroblast growth factor 21 was identified as a member of the subfamily of FGF19, the so-
called endocrine fibroblast growth factors, and was initially considered to be a mainly in liver 
produced hepatokine, inducing the adaptive response to starvation (97). The fibroblast growth 
factors family is an evolutionarily highly preserved group of growth factors. Among the 
vertebrate species, between 19 and 27 FGF genes have been identified. Both mice and 
humans possess 22 (FGF1 to FGF23, with FGF19 being the human orthologue of FGF15 in 
rodents), which are furthermore classified in seven subclasses based on their phylogenetic 
similarity (29,97). Emerging data though indicate FGF21 as a peptide hormone, with 
endocrine, paracrine and autocrine function, produced and acting in diverse tissues and 
overtaking a pivotal role in the regulation of metabolism. The stimuli for the expression of 
FGF21, the precise manner of action and the downstream signaling cascade are inherently 
complicated and not yet fully clarified (41,131).  
The signaling cascade of FGF21 is inducted through stimulation of its fibroblast growth factor 
receptor (FGFR) with seven isoforms having been identified hitherto in mammals, which are 
characterized as 1b, 1c, 2b, 2c, 3b, 3c and 4 (65). They are membrane receptors with an 
extracellular domain, which binds the ligand. They consist of three immunoglobulin-like 
subdomains, a transmembrane helix (a-helix) and an intracellular domain, which exhibits 
activity of tyrosine kinase. There is a very weak induction of downstream signal after the 
binding of FGFs to their relative receptors, so that the existence of an obligate co activator for 
the complete signal transduction was very early hypothesized. This co-activator is currently 
known to be the β-Klotho (KLB), an enzyme encoded by the KLB gene being the part of the 
three klothos subfamilies, α, β and γ (116). Different fibroblast growth factors show preference 
and affinity to different receptors. The preference of FGF21 has previously been reported to 
be FGFR1c/KLB and FGFR3/KLB (136,164). Howbeit, the 2c and 4 receptors have been 
suggested to be activated by FGF21 as well, even though with lower affinity (65,107). The 
downstream cascade is complicated and multidimensional, with the best described events 
being the stimulation of mitogen-activated protein-kinase (MAPK), a pathway which includes 
the RAF proto-oncogene serine/threonine-protein kinase (Raf-1) and the extracellular signal-
regulated kinases 1 and 2 (ERK 1, 2) (38,40,131). 
The first data emphasized the physiological and pathophysiological role of FGF21 in regulating 
mainly the glucose metabolism and energy expenditure, coordinating the response towards 
food deprivation (41). Further studies supposed the role of FGF21 in energy expenditure with 




(23,159). In addition to its role in energy expenditure, FGF21 was shown to have a role in 
improving metabolic biomarkers in diabetic monkeys and mice (64). Stepwise upregulation of 
FGF21 was observed after fasting and interestingly after consumption of a ketogenic diet (41).  
Both events include the reduction of supplied amino acids and the shift of metabolism towards 
catabolic processing of lipids in a common manner, which results in excessive amount of fatty 
acids.  The key event of this upregulation of FGF21 upon fasting and high-fat low carbohydrate 
ketogenic diets has been shown to be the fatty acids induced activation of peroxisome 
proliferator activated receptor a (PPARa), which is considered to be the upstream mediator of 
FGF21 (8).  
It is furthermore noteworthy that FGF21 can cross the brain blood barrier and pass intact to 
the brain in both humans and rodents, in an apparently unsaturable fashion, as there is a linear 
correlation between levels in plasma and cerebrospinal fluid (54, 138). Accordingly, the 
corresponding receptors FGFR1, FGFR2 and FGFR3 and the obligate co-receptor β-Klotho 
(KLB) can be detected in brain cells as well, although the ascertained amount of KLB is 
reported to be fairly low (83). One of the major sites of action of FGF21 intracerebrally seems 
to be the hypothalamic suprachiasmatic nucleus (SCN), which has been reported to be the 
crucial location of the FGF21 signaling in the central nervous system (41). The suprachiasmatic 
nucleus (SCN) is known to be a pivotal center for the circadian rhythmicity in vertebrates and 
overtakes an important role for the regulation of temperature, which could point to an 
interaction with the FGF21 induced thermogenesis in adipose tissue (113). Moreover, the 
crosstalk between FGF21 and SCN could create a circadian rhythmicity in diverse metabolic 
procedures. As it is known, the food intake in different time periods during the light and dark 
cycle can have dramatic effects on metabolism and a disruption in this rhythmicity could be 
one of the major contributors to obesity or diabetes mellitus (92). The SCN coordinates 
furthermore many behavioral performances and psychological processes (135). It is 
compelling to hypothesize that the function of FGF21 in this brain area could be a ligand 
between metabolism and behavior, as many metabolic disorders are accompanied with 
psychological distress and vice versa.  
The effect of FGF21 on ALD is binary and seems to affect both excessive alcohol consumption 
and progression of the hepatic damage itself. Given the metabolic and cholestatic 
modifications and complications of binge and chronic alcohol intake and the suggested 
metabolic role of FGF21, it was reasonable to be presumed that FGF21 could someway 
overtake a protective action against the pathophysiological and structural alterations, which 
ultimately lead to liver fibrosis and cirrhosis. Therefore, it can be furthermore intriguingly 
postulated that the activity of FGF21 in the central nervous system, especially its hypothalamic 




There are emerging data indicating an upregulation of plasma FGF21 in humans after binge 
alcohol drinking (27,67,128). Soberg et al. showed a 3.4-fold increase in FGF21 plasma levels 
in healthy and fasted volunteers after consumption of approximately 25.3 grams of alcohol 
(128). They further observed  2.1-fold increased levels of circulated FGF21 after binge drinking 
during three days (by healthy volunteers at the Oktoberfest), without any relevant induction 
through an aggravation of hepatic biomarkers (128). These findings are supported by the study 
of Lang et al. who documented a 9-fold increase in plasma levels of FGF21 after both oral and 
intravenous administration of ethanol (0,7g/kg body weight) (67). The upregulation of FGF21 
was observed approximately after 30 minutes (67). The authors could furthermore find out that 
this increase was accompanied with a decrease in insulin, C-peptide and glucagon with 
unaffected levels of gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP1), 
implying an incretin-independent influence of FGF21. The observed results were also 
independent from the route of alcohol administration. Desai et al. had previously demonstrated 
that upon binge alcohol intake, the peak of FGF21 elevation (in both mice and humans) occurs 
approximately one hour after consumption and FGF21 returns to the baseline about 6 hours 
afterwards (27).  
It was concomitantly intriguing that FGF21 seems to have an effect on drinking habits in both 
rodents and humans (42,84,119,154). A negative feedback circuit enorchestrated by FGF21 
has also been observed, which suppresses the appetite for alcohol consumption during the 
ongoing intake (42,84,119,154). Findings from rodents further supported the bidirectional 
correlation between alcohol intake and FGF21 levels (31,128,154). It has been recently shown 
that FGF21 suppresses the consumption of sugar and alcohol in mice by inhibiting their 
appetite for these (154). This was not surprising since alcohol is the product of alcoholic 
fermentation, which is the biologic process of conversion of sugars to glucose, fructose and 
sucrose. The latter becomes more meaningful considering that fructose intake is one of the 
most known factors that upregulates FGF21 (31). The intake of other macromolecules, such 
as lipids, proteins and complex carbohydrates seem to remain unchanged by FGF21 induction 
(154). Its direct effect on appetite is believed to be exerted via action in hypothalamic nuclei, 
as FGF21 can cross the blood-brain barrier and its main receptor FGFR1c and co-receptor 
KLB are expressed in many cerebral structures (154).   
Another interesting study from Song et al. confirmed an FGF21-mediated stimulation of water 
intake in response to alcohol consumption (and ketogenic diet as well) in a vasopressin 
independent manner (129). During alcohol intake this could be a counteractive mechanism 
targeting the alcohol dilution. Another study from Turner et al. has observed an increase in 




regardless of alcohol (149). These evidences, putting together, imply a new endocrine role of 
FGF21 in the regulation of serum and urine osmolality and balance of fluids and electrolytes. 
Summarizing the existing data, alcohol induced upregulation of FGF21 in serum has been 
documented in both humans and rodents. This induction of FGF21 expression in liver has been 
proposed to be hepatoprotective when liver homeostasis is challenged by various stimuli, as 
in the case of alcohol (27, 39). In the course of ALD, the main metabolic alterations in liver, 
including fat accumulation and a shift in bile acids biosynthesis and metabolism, are therefore 
supposed to be affected from alcohol induced FGF21. Thus, with the sparse and controversial 
preexisting evidences, the revealing interactions between FGF21 and bile acids metabolism 
were investigated in the present study. 
 
1.3 THE ROLE OF BILE ACIDS METABOLISM IN ALCOHOLIC LIVER 
DISEASE 
 
Bile acids (BA) are hydroxylated steroids produced by hepatic cholesterol metabolism through 
the catalytic activation of peroxisomal enzymes. Bile acid pool comprises various amphipathic 
acidic steroids that have important roles in the regulation of multiple functions in liver cells. In 
human primary bile acids are cholic acid and chenodeoxycholic acid, which are produced 
directly in the hepatocytes via a cytochrome-P450 mediated oxidation of cholesterol 
(18,51,114). The secondary bile acids are produced via bacterial actions in colon. In humans, 
the most important secondary bile salts are taurocholic acid and glycocholic acid (derivatives 
of cholic acid) and taurochenodeoxycholic acid and glycochenodeoxycholic acid (derivatives 
of chenodeoxycholic acid (51).  
In several studies, altered hepatic bile acid synthesis and hepatic accumulation have been 
found to be the potential major pathophysiological background for the induction of the structural 
and functional hepatocyte changes in both alcoholic steatohepatitis and non-alcoholic fatty 
liver disease (NAFLD) (16,157,158).  Because of their amphipathic chemical structure and the 
distinct biochemical properties a possible detrimental effect has been presumed for the 
hepatocyte in case of cholestasis (43). Two main factors which influence the cytotoxic potential 
of bile acids are their solubility in water and their conjugation with other molecules, such as 
glycine or taurine (52). The cytotoxic role of bile acids in the hepatocytes initially induces acute 
liver injury (ALI) in a case of insufficient activation of hepatoprotective mechanisms 
(46,117,157). The acute liver injury is defined as objectified hepatocellular damage upon a 




activities, conjugated bilirubin and alkaline phosphatase levels (117). If the cellular damage 
becomes persistent or permanent, the disease proceeds to chronic liver injury (CLI). The 
influence of the same or a different hepatoxic factor can cause a deterioration of the preexisting 
damage, a situation characterized as an acute on chronic liver injury (ACLI). Acute on chronic 
liver failure (ACLF) is defined as the rapid deterioration of a preexisting liver injury due to 
induction of a cascade of events, including inflammation, cytotoxicity and systematic 
involvement where the liver fails in fulfilling its physiological metabolic role (117). The liver 
failure is associated with excessive morbidiy and mortality, dysfunction or failure of multiple 
organs and requires immediate treatment (6).  
The key events affecting BA metabolism upon alcohol consumption have been reported to be 
their increased levels in liver, increased reabsorption in the enterohepatic circulation and 
increased excretion of more lipohilic and toxic bile acids (78). Therefore, the bile acid feedback 
loop overtakes an essential role for protection from liver damage. The major part of bile acids 
in liver is conjugated to glycine, taurine and sulfate (20,78).  They are transported through the 
bile ducts in the duodenum, where they assist the emulsification of lipids, together with biliary 
lecithin (30,143). The BA micelles are then reabsorbed in the distal ileum, leading the way to 
enterohepatic circulation, in order for excessive intestinal loss to be avoided. So the negative 
feedback loop is constituted by the hepatic reabsorption of bile acids, which further inhibits 
cholesterol conversion and BA biosynthesis partly (30,141,143).  
Bile acids stimulate many receptors such as the Farnesoid X Receptor (FXR) and a G protein-
coupled receptor (TGR5) (141). The BA signaling via FXR seems to enorchestrate hepatic and 
intestinal functions, whereas the stimulation through TGR5 exerts endocrine, metabolic and 
neurologic actions (37). The critical rate-limiting step of BA biosynthesis is the expression of 
the enzyme cholesterol 7 alpha-hydroxylase (CYP7A1), which oxidizes cholesterol in the 
position 7 using molecular oxygen (18,114). CYP7A1 induces the classical BA synthesis 
pathway, in which the relative amount of primary bile acids is regulated through CYP8B1, which 
is a sterol 12-a-hydroxylase, located in the membrane of endoplasmic reticulum (19,20). The 
catalytic action of CYP8B1 leads to preferred synthesis of cholic acid, whereas 
chenodeoxycholic acid is produced in its absence. There is an alternative (acidic) pathway for 
BA synthesis that is mediated through sterol-27-hydroxylase (CYP27A1), which is a 
cytochrome P450 oxidase located in mitochondria (Figure 4). It is the initiating enzyme of this 
pathway and believed to overtake an upgraded role in the metabolism of BA in the presence 







Figure 4: Classical and alternative pathways of the bile acids biosynthesis. AKR: Aldo-Keto Reductase 
Family, CYP: Cytochrom P450, HSD: Hydroxysteroid Dehydrogenase. Adapted from Journal from 
Hepatology (20). 
 
The feedback regulation of the CYP7A1 has been shown to be mediated mainly by a nuclear 
receptor signaling cascade including FXR and the small heterodimer partner (SHP) 
(37,78,157). Induction of intestine farnesoid X receptor/fibroblast growth factor 19 
(FXR/FGF19) and activation of the farnesoid X receptor/small heterodimer partner (FXR/SHP) 
axis in liver by elevated bile acid levels have been suggested to be the main mechanisms for 
inhibition of bile acid synthesis, through suppression of CYP7A1 transcription (37,78,157). This 
repression takes place, because elevated bile acid concentrations in the ileum activate FXR, 




and the consequential stimulation of fibroblast growth factor receptor 4 (FGFR4)/β-Klotho 
(KLB) complex in the hepatocyte membrane (37,78,157). Furthermore, a recently discovered 
protein, DIET1, has been suggested to be a regulator of FGF15/19 and its suppressive role in 
BA synthesis (152). DIET1 is a highly conserved protein, consisting of 2.123 amino acids, 
which is mainly expressed in the epithelial cells of the intestine (152). Vergnes et al. proved 
that DIET1 deficiency causes decreased levels of intestinal FGF15 in mice causing a negative 
impact on the ability of the bile acids regulation in the enterohepatic circulation (152). As a 
conclusion, the intact production and function of DIET1 appears to be an important factor for 
the integrated signaling in the FXR-FGF15/19-BA feedback loop, at least at the first part of the 




Figure 5: The negative feedback circuit of the regulation of bile acids biosynthesis through stimulation 
of FXR and induction of FGF15/19.CYP7A1: cholesterol 7 alpha-hydroxylase FGF15/19: Fibroblast 
Growth Factor 15/19, FXR: Farnesoid X Receptor, FGFR4: Fibroblast Growth Factor Receptor 4, KLB: 





A previously unidentified role of FGF21, as a negative regulator of bile acid (BA) synthesis, 
has been described recently (17,163). Chen et al. showed hence that FGF21 is a negative 
regulator of BA synthesis and supported its activation in an FGF15/19 independent manner 
(17). However, the underlying mechanisms of this effect remain unclear. It is howbeit 
reasonable to hypothesize that the signal transduction happens in one of the identified 
downstream signaling pathways of FGF21. FGF21 initially binds to the complex of KLB with 
one of its main receptors (FGFR1c, FGFR2c, FGFR3c and FGFR4) (2) and leads to activation 
of two main downstream pathways including the extracellular-signal-regulated kinases/ 
Mitogen-activated protein kinase (ERK/MAPK) and the mammalian Target of Rapamycin 
(mTOR) pathways (85). However, the role of FGF21 in biosynthetic regulation of bile acids has 
been shown to be more controversial and remains to be clarified.  
The supported suppression of PPARa through SHP could lead to the initial hypothesis that 
FGF21 suppression is a predisposition to CYP7A1 suppression (163). This implies an 
antagonistic role for FGF15/19 and FGF21, concerning the regulation of BA production. 
Although the signaling cascades are not well known, Minard at al. has supported that the major 
signaling of FGF21 occurs through mTORc1 in adipocytes (85). In hepatocytes, FGF21 has 
been suggested to induce the phosphoinositide 3 kinase/protein Kinase/mammalian target of 
Rapamycin (PI3K/AKT/mTOR) downstream signaling cascade, a fact that further implies 
mTOR as crucial node for FGF21 action in liver (90). Another potential signal mediation of 
FGF21 in the hepatocytes via the PI3K/AKT pathway suggests a possible role of a member of 
the sterol regulator element binding proteins (SREBPs), SREBP-1c, as a mediator of FGF21 
signaling. There is a previous evidence that the PI3/AKT pathway is involved in the control of 
SREB1c mRNA expression levels (47). Moreover, SREBP1c is positively correlated with non-
alcoholic fatty liver disease (NAFLD), probably activating the expression of PNPLA3 gene and 
promoting fat accumulation in liver (87,109,130). In this context, there is emerging evidence 
for the existence of an FGF21-SREBP1c pathway, which acts as negative feedback circuit 
(166). 
Although the concrete roles of FGF21 and FGF15/19 in ALD have not been studied in details 
yet, there are published evidences for their hepatoprotective role in liver damage regardless 
of causative background (27,39,153). An early observation was the contribution of FGF15/19 
mediated reduction of bile acids synthesis to the attenuation of liver damage, by ameliorating 
cholestasis (86). This positive effect is howbeit to a certain degree counteracted through the 
mitogenic effect of FGF19, which has been suggested to promote HCC development both in a 




course of an acute or chronic liver damage this ambiguous biological behavior becomes 
relevant. It could for instance offer an explanation for the fact that a preexisting steatosis 
negatively affects the liver ability to be regenerated (21,53,62). Consistent evidence has also 
emerged for the potential hepatoprotective role of FGF21 (27,39,160). As more detailed cited 
above the alcohol intake is a robust inducer of elevated plasma levels of FGF21. This 
upregulation could furthermore be ascertained under conditions of liver injury challenged by 
various stimuli in addition to alcohol challenge (160), which could be PPARa dependent or 
independent (122). In addition, the significance of the elevated levels of FGF21 has been 
proved by showing a deterioration of liver damage upon hepatotoxic agents in Fgf21 knock out 
(KO) mice as compared with their wild type counterparts (122).  
Moreover, the role of the BA in the physical course of liver disease poses the question about 
possible pharmacological effect of the lipophobic and cytoprotective ursodeoxycholic acid 
(UDCA) on cholestatic damage caused by alcohol. Positive evidence has indicated that UDCA 
and TUDCA (tauroursodeoxycholic acid, the conjugated molecule) proved a favorable effect 
against liver damage in human hepatoblastoma (HepG2) and hepatoma (SK-Hep-1) cells 
(24,50,94). Convincing data for the hepatoprotective role of UDCA in alcoholic liver disease 
denoted analogous treatment efforts in rodent livers (96). These data urged the beginning of 
clinical trials in patients with alcoholic cirrhosis, howbeit with hitherto controversial results. 
During clinical trials of control of UDCA versus placebo, the use of UDCA resulted in significant 
decrease of transaminases and bilirubin in the UDCA treated groups, but lower survival rates 
and more complications as well (102,105). The emerging data are auspicious but mandate 
further evaluation to establish a potential pharmacological value for UDCA. What furthermore 
remains unclear is the precise mechanism of amelioration of alcohol induced liver damage via 
UDCA, with many proposed pathways, such as improving impact on ATP synthesis in 
mitochondria, decrease of oxidative stress and oxidative damage and restoration of 
intracellular Prostaglandin E and linoleoyl-CoA-desaturase (75,93,137,151). All the above 
pathways are altered and become dysfunctional in the physical course of a liver injury.  
In summary, it is compelling to clarify if and alcohol induced serum FGF21 targets not only the 
suppression of further intake via hypothalamic stimulation but also the early development of a 
defensive mechanism against liver damage. Previous studies support its hepatoprotective 
effect against liver damage of different etiologies. In addition to its hepatoprotective role, its 
recently revealed role in BA metabolism needs further investigation, in both healthy liver and 
during cholestasis. Therefore, in this study, the crosstalk and interactions between FGF21 and 
bile acids was investigated after chronic plus binge alcohol consumption in an alcohol related 




1.4 CHARACTERIZATION OF THE MOUSE MODEL 
 
In the conducted murinal experiments, mice with previously healthy liver (C57BL/6J) and a 
mouse model with a preexisting liver damage (Abcb4−/−) have been used. C57BL/6J is a 
commonly used inbred mouse type and represents a good model for biological studies of 
several disease patterns, like atherosclerosis, obesity and diabetes (99,118). This mouse 
model drinks alcoholic beverages deliberately, which made it an ideal candidate for the 
planned studies with use of ethanol including diets. The model has been previously widely 
used and its characteristics and behavior are predictable (10). 
The ATP-binding cassette 4 gene (Abcb4) knockout mice, also referred as multidrug resistance 
protein 2 (Mdr2) knockout, represent a model with a preexisting cholestatic liver injury, 
mimicking primary sclerosing cholangitis and biliary fibrosis (9). ABCB4 is a member of the 
family of ATP–binding cassette transporters and MDR/TAP subfamily. The proteins of the 
superfamily are translocators, enabling the intra- and extracellular transportation of various 
molecules (9,108). The proteins of the MDR subfamily undertake various functions, such as 
development of multidrug resistance (as the name of the subfamily implies), antigen 
presentation during the immune response and function as membrane transporters (9,108). In 
this frame, ABCB4 is implicated in the transportation of phosphatidylcholine from the 
hepatocytes into the bile, acting as member of the p-glycoprotein family of membrane proteins. 
In this way, it can be characterized as a floppase, namely a lipid-transporting glycoprotein, 
located on the cytoplasmic membrane, with transporting direction from the cytosol to the 
extracellular space (9,108). Its exact role has not been fully elucidated, but it is supported to 
have a crucial task in the excretion of phospholipids generally into the bile. Supporting for this 
is the fact, that the ABCB4 transporter on the hepatocytes is almost exclusively located on the 
canalicular side of the membrane (108). Consequently, an ABCB4 deficiency results in an 
unfavorable change in the proportion of phosphatidylcholine to bile salts in the bile acids pool, 
which precipitates the induction of cholestatic liver damage (108). In liver, phosphatidylcholine 
is the most abundant phospholipid and its alterations in the presence of ABCB4 deficiency are 
considered to occur due to changes in biosynthesis, catabolism and secretion into the bile and 
plasma. However, the secretory defect is suggested to bear the most crucial role for the 
pathogenetic cascade ultimately leading to cholestasis (9). 
The cholestatic profile of Mdr2 knockout mice has been indeed described in a previously 
published study, where a nearly completely lack of cholesterol and phosphatidylcholine in the 
homozygous deficient mice and a consequent cholestatic liver disease was ascertained (126). 




of protective micelles with both cholesterol and bile salts (146). The Mdr2 deficient mice 
develop gradually biliary fibrosis (similar to primary sclerosing cholangitis) and have elevated 
risk of HCC (35). A similar cholestatic pattern appears in humans with MDR3 (the human 
orthologue of murinal MDR2) deficiency (26). These patients have a markedly elevated 
potential to develop progressive familial intrahepatic cholestasis type 3. They show 
furthermore a predisposition for drug-induced liver damage and the females for intrahepatic 
cholestasis of pregnancy (26). The pathophysiological background is similarly the decreased 
amount of excreted phosphatidylcholine into the bile, through a defect of the canalicular 
transporter (26). 
In the current study, the Abcb4−/− mouse model was combined with a standardized chronic-
plus-binge ethanol feeding model (NIAAA) described previously by Bertola et al. (10). This 
model has been suggested to represent in a satisfactory way the pattern of alcohol abuse in 
patients with alcoholic liver disease and could therefore offer the preconditions to compare the 
findings of the murinal studies with those of the translational studies in human patients. An 
alternative alcohol consumption pattern of ad libitum alcohol ingestion for 4-6 weeks causes 
only mild hepatic fat accumulation, without virtually induction of inflammation or severe grade 
of steatosis (10). Thus, it has not been considered as an adequate experimental model for 
detection of the impact of alcohol on the biosynthesis of the bile acids and the endocrine 
fibroblast growth factors. 
Bertola et al. have also used the C57BL/6J mouse model and combined ad libitum ethanol 
including diet (5% v/v ethanol liquid diet) for a time period of ten days with a following insult of 
binge alcohol intake (10). More recently, applying the above mentioned NIAAA feeding model, 
a mouse model with the Abcb4/Mdr2-/- genotype was established by Karatayli et al. Since the 
Abcb4 knockout mice display the prediscussed cholestatic liver injury, additional excessive 
alcohol ingestion acts in this frame as a second insult, which deteriorates the preexisting 
pathology, leading either to a histological and biochemical worsening (ACLI, acute on chronic 
liver injury) or to a complete loss of the major hepatic functions (ACLF, acute on chronic liver 
failure). The biochemical and histopathological findings of the proposed mouse model 
established by Karatayli et al. has been shown to be a novel promising approach to model 
alcohol-related ACLI (61), which represents a reliable and convincing pattern for the physical 







2. STUDY AIM 
 
In the current study, we aimed to investigate the impact of chronic plus binge alcohol intake on 
tissue production and circulating levels of FGF21 and FGF15/19 and bile acid metabolism in a 
recently established ACLI mouse model with preexisting chronic cholestatic liver injury (61). It 
was initially hypothesized that ethanol intake will upregulate both hepatic expression of FGF21 
and ileal expression of FGF19 and that the elevated production of these endocrine fibroblast 
growth factors will suppress the rate of bile acids synthesis, thus ameliorating ethanol-induced 
liver injury. It was further suggested that FGF21 would have a direct impact on regulating bile 
acid synthesis, acting independently of FGF15/19 in the enterohepatic circulation. It was 
assumed that the suggested ethanol-induced upregulation of FGF15/19 and FGF21 will be 
preserved even in the frame of preexisting cholestatic liver injury.  
For this purpose, an animal study was conducted by using wild-type (WT, C57BL/6J) mice and 
the ethanol-induced acute-on-chronic liver injury (ACLI) model in Abcb4-/- mice (KO). By using 
different mouse groups, either fed control diet (WT/Cont and KO/Cont groups) or ethanol diet 
(WT/EtOH and KO/EtOH groups), the impact of chronic plus binge alcohol-induced FGF21 on 
bile acid metabolism should be investigated. To investigate the direct effect of FGF21 in vitro, 
recombinant human FGF21 was added to primary mouse hepatocytes. Finally, we assumed 
that our preclinical findings would sufficiently resemble the pathophysiological alterations of 
bile acid metabolism and endocrine fibroblast growth factors in human patients with alcohol-
associated liver disease and ongoing alcohol use disorder. In order to translate the findings 
from mouse studies, human subjects with ongoing alcohol consumption and alcoholic liver 












3. MATERIAL AND METHODS 
 
3.1 STUDY DESIGN 
 
3.1.1 MURINAL EXPERIMENTS 
In order to clarify the impact of alcohol intake on the endocrine fibroblast growth factors and 
the biosynthesis of bile acids, both in a healthy liver and by preexisting cholestatic liver disease, 
we designed an experimental study with two mouse genotypes, the first wild type (WT, 
C57BL/6J) and the second with a cholestatic liver pattern, similar to primary sclerosing 
cholangitis (Abcb4 KO mice). Each group consisted of 56 mice, with equal number of males 
and females. The two groups were furthermore divided into two subgroups, the first fed with 
control diet and the second with ethanol diet. The used diet models are described in detail 
below and rely on previously described models. We determined following parameters at the 
baseline and after ethanol challenge: aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), gamma glutamyl-transferase (GGT), serum ethanol, bile acids, 
FGF15, FGF21 and mRNA expression levels  of sterol regulatory element binding transcription 
factor 1 (Srebf1), Fibroblast growth factor receptor 4 (Fgfr4), Fibroblast growth factor receptor 
1 (Fgfr1), cytochrome P450 family 7 subfamily A member 1 (Cyp7a1), Fibroblast growth factor 
21 (Fgf21), Farnesoid X-Activated Receptor (Fxr/Nr1h4), Klotho beta (Klb), Mechanistic target 
of rapamycin (Mtor), Peroxisome proliferator activated receptor alpha (Ppara), Small 
heterodimer partner (Shp/Nr0b2), Cytochrome P450 family 27 subfamily A member 1 
(Cyp27a1), and Cytochrome P450 family 8 subfamily B member 1 (Cyp8b1) as well as ileal 
mRNA levels of MAM and LDL receptor class A domain-containing 1 (Malrd1/Diet1), Fibroblast 
growth factor 15 (Fgf15) and Farnesoid X-Activated Receptor (Fxr/Nr1h4). After the sacrifice 
of the mice liver tissue was obtained to perform histological evaluation. Our aim was to detect 
any changes to the aforementioned parameters after ethanol intake in both genotypes and any 
differentiations between the two genotypes. 
 
3.1.2. TRANSLATIONAL STUDIES 
We recruited 31 volunteer patients with formerly diagnosed alcoholic liver disease (24 men, 7 
women) and admitted ongoing daily ethanol consumption and 27 healthy volunteers (14 men, 




hemoglobin, who denied ethanol intake for the last 7 days prior to the conducted blood tests. 
The main cohort characteristics are described below. To objectify and approximately quantify 
the alcohol consumption (or its absence) we measured serum levels of carbohydrate deficient 
transferrin (CDT) in all human subjects. We determined serum levels of FGF19, FGF21, bile 
acids and oxysterols (7α and 27-hydroxycholesterol -7αOHC and 27OHC-, respectively). The 
serum oxysterols were used as biomarkers of the activity of the bile acids biosynthesis 
cascade. Our aim was to detect any differences in the levels of the endocrine fibroblast growth 
factors and the biomarkers of bile acids synthesis in the presence of alcohol consumption by 
preexisting liver damage. 
 
3.2 MOUSE MODELS 
 
For the murinal studies two mouse groups were used, consisting of fifteen week-old wild-type 
mice (C57BL/6J, n= 56) and Abcb4 knock-out mice (Abcb4−/−, n= 56). The accommodation 
took place under conditions of controlled humidity and temperature and ascertainment of a 12-
hour light and 12-hour dark cycle. Based on the models described by Bertola et al (10) and 
Karatayli et al (61) each mouse group was divided into two subgroups, either fed control diet 
(WT/Cont and KO/Cont groups) or ethanol diet (5% v/v), followed by a subsequent acute 
ethanol intake (4 g/kg body weight) (WT/EtOH and KO/EtOH groups; n= 28 per group). The 
numbers of male and female mice were equal in the two groups and four subgroups. The body 
weight of the mice was monitored daily. In this way the recently established acute on chronic 
liver injury (ACLI) model was established, where Abcb4-/- was combined with a predefined 
chronic-plus-binge ethanol feeding model (NIAAA) (61). According to the aforementioned 
studies, the mice were initially fed with an ad libitum liquid diet (Rodent liquid diet, Lieber-
Decarli 82; Bio-Serv, Frenchtown, NJ, USA) for five days. At the end of the 5th day, the mice 
diets were switched to either control liquid diet or ethanol diet (Rodent liquid diet, Lieber-Decarli 
82-ethanol 4% v/v; Bio-Serv, Frenchtown, NJ, USA) for a period of 10 days, with subsequent 
application of isocaloric maltose dextrin gavage (9 g/kg body weight) or by an acute ethanol 
binge (4 g/kg body weight), respectively. All mice were sacrificed 7-9 h after gavage and 
plasma samples were acquired from whole blood assembled from the inferior vena cava. The 
harvested liver and intestine tissue samples were frozen in liquid nitrogen and stored at −80°C. 
Bile collected from the gallbladder was stored at -20°C. All experiments were performed in 
accordance with the relevant regulations of the Animal Care and Use Committee for Saarland 
University and were approved by Saarland University Animal Ethics Committee (TV 44/2015 




3.3 MEASUEREMENT OF PLASMA BIOCHEMICAL MARKERS 
 
Carbohydrate-deficient transferrin (CDT) was determined by using “The Siemens N Latex CDT 
kit” (BNII; Siemens Healthcare Diagnostics,Erlangen,Germany). Alanine aminotransferase 
(ALT),  aspartate aminotransferase (AST) and ethanol (EtOH) levels were measured in plasma 
(Roche Cobas 8000 c702 modular analyzer) in the Central Laboratory of Saarland University 




The collagen accumulation in mouse liver and the inflammation grade were evaluated by Sirius 
Red histochemistry and hematoxylin-eosin (H&E) staining, respectively. For histopathological 
analysis, paraffin-embedded, 5 μm thick formalin-fixed (4%, v/v) liver sections were used. The 
grading of liver fibrosis and the quantitative evaluation of inflammation were performed by 
means of a histomorphometric semi-automatic system for image analysis (Leica microscope, 
equipped with Leica application suite software; Wetzlar, Germany). An evaluation of five 
randomly chosen microscopic areas took place for each Sirius Red stained liver section, in 
order to calculate the percentage of collagenous area. H&E stained sections were also applied 
to find out infiltration through inflammatory cells and to calculate the dimensions of lipid 
droplets.   
  
3.5 DETERMINATION OF PLASMA FGF15/19 AND FGF21 LEVELS  
 
The plasma levels of FGF21 and FGF15 in mice were determined by means of the FGF-21 
Quantikine ELISA Kit (MF2100; R&D Systems, Minneapolis, MN, USA) and mouse FGF15 
ELISA kit (RD-FGF15-Mu; Reddot Biotech, Kelowna, BC, Canada). Human FGF-21 
Quantikine ELISA kit (DF2100; R&D Systems) and Human FGF-19 Quantikine ELISA kit 
(DF1900; R&D Systems) were used for the quantification of FGF21 and FGF19 levels in 
human plasma samples. Each plasma sample was studied in duplicates, and average values 






3.6 PRIMARY HEPATOCYTE ISOLATION, CULTURE AND TREATMENT 
 
The primary murinal hepatocytes (HC) were obtained from C57BL/6J mice (8–15 week old) 
using the collagenase perfusion method. The acquired HC were subsequently seeded in 6 well 
collagen-I-coated (collagen from rat tail, Sigma-Aldrich, St. Louis, Missuri, USA) cell culture 
plates at a density of 3x105 viable cells per well and incubated in 5% CO2 at 37°C for four 
hours. After that the cells were attached by means of incubation with medium 1 (Williams’ 
medium E supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1% 
penicillin/streptomycin, 100 nM dexamethasone). The medium was followingly switched to 
medium 2 (medium 1 without FBS) for serum starvation and cell cycle synchronisation. After 
20 h, graded and no graded concentrations of recombinant human FGF21 (rhFGF21) (0.1, 
0.25, 0.5, and 1 µg/ml, R&D Systems) were injected to the cells in medium 3 (Williams’ medium 
E supplemented with 2 mM L-glutamine and 1% penicillin/streptomycin) for 24 h. 
Subsequently, RNA extraction and gene expression analysis were performed and PBS was 
included as control. All the above mentioned experiments were conducted in triplicates, and 
each experiment was performed three times. 
 
3.7 RNA ISOLATION AND QUANTITATIVE REAL-TIME PCR ANALYSIS  
 
The total RNA was acquired from frozen liver tissues by means of RNeasy Mini kit (Qiagen, 
Hilden, Germany). For ileum tissues and cells from cell culture peqGold Microspin total RNA 
kit (VWR, Erlangen, Germany) was utilized. The reverse-transcription of the obtained total 
RNA was conducted using the High Capacity cDNA Reverse Transcription Kit (Life 
Technologies, Carlsbad, CA, USA). The cDNA was amplified in 96-well plates via TaqMan™ 
Fast Universal PCR Master Mix (2x) (Applied Biosystems/Thermo Scientific) on a Taqman 
7500 Fast Real-Time PCR system. The evaluation of hepatic steady-state mRNA expressions 
of Sterol regulatory element binding transcription factor 1 (Srebf1, Mm00550338_m1), 
Fibroblast growth factor receptor 4 (Fgfr4,  Mm01341852_m1), Fibroblast growth factor 
receptor 1 (Fgfr1, Mm00438930_m1), cytochrome P450 family 7 subfamily A member 1 
(Cyp7a1, Mm00484150_m1), Fibroblast growth factor 21 (Fgf21, Mm00840165_m1), 
Farnesoid X-Activated Receptor (Fxr/Nr1h4, Mm00436425_m1), β-Klotho (Klb, 
Mm00473122_m1), Mechanistic target of rapamycin (Mtor, Mm00444968_m1), Peroxisome 
proliferator activated receptor alpha (Ppara, Mm00440939_m1), Small heterodimer partner 




(Cyp27a1, Mm00470430_m1), and Cytochrome P450 family 8 subfamily B member 1 
(Cyp8b1, Mm00501637_s1) as well as ileal mRNA levels of MAM and LDL receptor class A 
domain-containing 1 (Malrd1/Diet1, Cg04494263_m1), Fibroblast growth factor 15 (Fgf15, 
Mm00433278_m1) and Farnesoid X-Activated Receptor (Fxr/Nr1h4, Mm00436425_m1) was 
performed via TaqMan gene expression assays (Applied Biosystems). The ΔΔCt algorithm 
was applied for the determination of the relative alterations of gene expressions. In the latter 
procedure Glyceraldehyde-3-phosphate dehydrogenase (Gapdh, Mm99999915_g1) was used 
as internal control.  
 
3.8 TOTAL BILE ACID MEASUREMENT OF MOUSE PLASMA AND 
GALLBLADDER 
 
The collected bile acid samples were acquired from a total of 37 mice (11 WT/Cont, 11 
WT/EtOH, 9 KO/Cont, and 6 KO/EtOH). The measurement of the total bile acid levels (TBA) 
was performed with the “Total Bile Acids Enzymatic Colorimetric Kit” (Cat.No. BI 3863; Randox 
Laboratories, Crumlin, UK) according to the manufacturer’s instructions. The taurocholic acid 
standard was made from powdered taurocholic acid in methanol and afterwards stored at -
20°C. The prepared standard was next used in different dilution series for gallbladder (range 
between 5-160 µM) and plasma samples (range between 0.5-60µM). The samples were 
studied in duplicates and the average values were utilized for analysis. Two absorption 
measurements were performed in the microplate reader at 405 nm at times t0 and t1 (two 
minutes later than t0). The difference in absorbance E (t1) - E (t0) is regarded to be proportional 
to the serum concentration of bile acids. The proportionality factor was matched to the gradient 
of the standard dilution curve. 
 
3.9 ANALYSIS OF SERUM TOTAL BILE ACID AND CHOLESTEROL 
LEVELS IN HUMANS 
 
The “LT-SYS ® Gallensäuren Test” (LT-SYS Diagnostics, Berlin, Germany) with the Randox 
calibrator Cal 2351 was used to perform the measurements of the serum levels of total bile 
acids. Total cholesterol levels were measured using the enzymatic colorimetric determination 




measurements were conducted in the Central Laboratory of Saarland University Medical 
Center. 
 
3.10 QUANTIFICATION OF SERUM CONCETRATIONS OF OXYSTEROLS  
 
The quantification of the serum levels of 7α and 27-hydroxycholesterol (7αOHC and 27OHC, 
respectively) were quantified by means of isotope dilution GC-mass spectrometry selected ion-
monitoring (GC-MS-SIM) methodology, using the corresponding deuterium labelled oxysterols 
as internal standards. The measurements were conducted in the laboratory of Professor 
Lütjohann et al., at University Medical Center of Bonn, Germany. 
 
3.11 HUMAN SUBJECTS 
 
Volunteer patients with preexisting alcoholic liver disease (n=31; 24 men, 7 women) and 
healthy controls, without any known preexisting liver disease were included in the study (n=27; 
14 men, 13 women), after providing their written informed consent. The general clinical 
characteristics of the two groups are summarized in Table 2. The recruitment of the patients 
with alcoholic liver disease took place after hospital admission in the Clinic of Gastroenterology 
and Hepatology of the University Medical Center of Homburg, Saarland, Germany, due to 
decompensation of the disease and admitted ongoing daily alcohol consumption (30-100 
g/day) for at least one week prior to hospitalization. The precise amount of alcohol consumption 
could not be measured. We therefore conducted evaluation of serum levels of carbohydrate 
deficient transferrin (CDT) as biochemical marker for the alcohol consumption. All the 
volunteers of the cohort of healthy controls reported no history of liver diseases or intake of 
medication. Their Body-Mass Index (BMI) and serum levels of glycated haemoglobin (HbA1c) 
were within the reference ranges. The study with human subjects was approved by the Ethic 


















Data are mean ± standard deviation (range). 
Table 2: General clinical and biochemical characteristics of healthy control and ALD cohorts. AST: 
aspartate transaminase, ALT: alanine transaminase, GGT: gamma-glutamyl transferase, CDT: 
carbohydrate deficient transferrin, BMI: Body Mass Index, HbA1c: glycated haemoglobin, ALD: alcoholic 
liver disease 
 
3.12 STATISTICAL ANALYSIS 
 
Statistical analysis was conducted by means of SPSS v18.0 (IBM, Armonk, NY, USA) and 
GraphPad Prism (GraphPad Software, CA, USA). All data was expressed with mean and 
standard error (mean ± SE). A two-tailed Student's t-test was used for the comparison between 
two groups and one-way ANOVA followed by post hoc (Bonferroni) correction was applied for 






 Healthy controls ALD patients 
N (women/men) 27 (14/13) 31 (7/24) 
Age range (years) 36 ± 10 (24 - 70) 55 ± 11 (33 - 81) 
AST (IU/l) 23 ± 7 (18 - 47) 63 ± 44 (17 - 174) 
ALT (IU/l) 22 ± 11 (10 - 62) 47 ± 41 (12 - 122) 
GGT (IU/l) 18 ± 6 (6 - 35) 237 ± 241 (44 - 1076) 
CDT (mg/ml) 34 ± 8 (24 - 51) 51 ± 17 (24 - 79) 
Total cholesterol(mg/dl) 181 ± 37 (121 - 262) 154 ± 69 (60 - 393) 
Triglycerides (mg/dl) 95 ± 58 (36 - 142) 105 ± 71 (39 - 367) 
BMI (kg/m²) 22.7 ± 1.2 (20.7 - 24.9) 25.8 ± 3.0 (20.4 - 31.2) 






4.1 EFFECTS OF ETHANOL CONSUMPTION ON PLASMA AST, ALT AND 
ETHANOL LEVELS IN MICE 
 
In order to objectify the impact of ethanol ingestion on hepatic biomarkers, we determined the 
serum aminotransferase activities (aspartate aminotransferase - AST and alanine 
aminotransferase - ALT) and serum ethanol (EtOH) levels before and after the alcohol intake 
in both mouse types. Ethanol could not be detected in serum before the exogenous application 
and could be confirmed after it. Serum aminotransferase activities showed significant elevation 
in both mouse types after the ethanol application (p< 0.001 for ALT and p = 0.013 for AST in 
wild type, p=0.001 for ALT and p=0.001 for AST in KO mice) (Figure 6). The latter observation 
indicates the induction of a marked hepatocellular reaction, in both previously healthy and pre-




Figure 6: Plasma levels of ethanol (A) and biochemical markers ALT (B) and AST (C) in mice. ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; EtOH, ethanol; KO, Abcb4 knock-out mice; 








4.2 EFFECT OF ETHANOL CONSUMPTION ON FGF21 EXPRESSION IN 
HEPATOCYTES AND CIRCULATING LEVELS OF FGF21 IN MICE 
 
Ethanol ingestion caused a significant upregulation of the expression of the Fgf21 gene  in 
both WT and KO mice (p=0.009 and 0.011 respectively), compared to their normal diet fed 
counterparts.  No significant difference was observed between the two genotypes (Figure 7A). 
This fact indicates a preserved hepatic ability for upregulation of FGF21 upon ethanol 
consumption even in the setting of preexisting cholestatic damage. The upregulation of  the 
hepatic production of FGF21 was furthermore mirrored in significantly elevated levels of 
circulating FGF21 in WT and KO mice after the ethanol challenge (p=0.04 and 0.048 
respectively). The latter observation is consistent with the previously supported fact  that 
FGF21 is a primarily hepatokine and the  liver expression confers the major part of its 
circulating levels (Figure 7B).  
 
 
                                                                                     
Figure 7: Effect of ethanol on FGF21 in liver and plasma. Relative quantification of Fgf21 mRNA levels 
in liver (A). Plasma FGF21 levels were quantified by ELISA (B).. Cont, Control diet; EtOH, Ethanol diet; 








4.3 EFFECT OF ETHANOL CONSUMPTION ON HEPATIC PPARA, 
FGFR1, KLB, MTOR AND SREBF1 MRNA EXPRESSION LEVELS 
 
Furthermore, the impact of alcohol on FGF21 signaling pathways was examined. In order to 
achieve this, hepatic mRNA levels of the Ppara (FGF21 upstream inducing mediator), Mtor 
(FGF21 downstream transducing signaling mediator) and Srebf1/Srebp1c genes (transcription 
regulator) were evaluated. The expression of hepatic Ppara showed significant upregulation 
after the ethanol ingestion in both WT and KO mice (p=0.01 and p=0.02, respectively), howbeit 
no difference was observed between the two genotypes (Figure 8A). Despite this fact, no 
significant difference was ascertained, as far as the hepatic mRNA expression of Mtor and 
Srebf1/Srebp1c between the two groups is concerned (Figure 8 B-C). More interestingly, there 
was noted no significant effects of ethanol intake on hepatic mRNA expression levels of 
FGFR1, which is the preferred receptor of FGF21, and its obligate co-receptor beta-klotho 
(KLB) (Figure 8 D-E). The above mentioned results in summary support the upregulating 
impact of alcohol on FGF21 by means of an upstream induction of PPARa but without 
alterations in the levels of the transcription factor SREBF1. In addition, our experiments 
indicate that the downstream signal transduction of FGF21 upon ethanol challenge is 
conceivably not mediated through the mTOR signaling pathway. 
 
Figure 8: Relative quantification of hepatic mRNA levels. Transcriptional levels of Ppara (A), Mtor (B), 
Srebf1 (C), Fgfr1 (D) and Klb (E) were determined by qPCR. Cont, Control diet; EtOH, Ethanol diet; KO, 




4.4 EFFECT OF ETHANOL INTAKE ON CYP7A1, CYP27A1, CYP8B1 
AND BILE ACID SYNTHESIS 
 
Hepatic expression of Cyp7a1 and Cyp27a1, which encode cholesterol 7 alpha – hydroxylase 
(CYP7A1) in the classic and sterol 27-hydroxylase (CYP27A1) in the alternative BA synthesis 
pathway, were both significantly repressed in WT/EtOH mice (p<0.001 and 0.012, 
respectively). In the KO/EtOH mice was observed only a statistically significant suppression of 
Cyp7a1 (p<0.001) but not Cyp27a1 (Figure 9A-9B). Significant repression of Cyp8b1 gene, 
encoding sterol 12α-hydroxylase (CYP8B1), which is required for synthesis of cholic acid, was 
observed only in KO/EtOH group compared with the WT/Cont (p=0.041), WT/EtOH (p=0.029) 
and KO/Cont groups (p=0.027) (Figure 9C). Although statistically not significant, chronic plus 
binge ethanol feeding increased TBA levels both in plasma and gallbladder bile in mice (Figure 
9D-9E), showing higher plasma TBA levels in KO/Cont as compared to WT/Cont mice. These 
data indicate that gene expression involved in the bile acid synthesis cascade was reduced, 
although the bile acid pool size of gallbladder and plasma samples were increased after alcohol 
feeding. Together these results indicate a trend to secondary protective suppression of the 
cascade of bile acid synthesis, following the induction of hepatic FGF21 production after 
ethanol intake. It is furthermore intriguing that the suppression of Cyp8b1 in the KO mice could 
suggest an altered balance between the two primary bile acids, cholic acid and 






Figure 9: Relative quantification of gene expression using qPCR in liver and TBA levels in plasma and 
gallbladder. Hepatic mRNA levels of bile acid synthesis genes( Cyp7a1 (A), Cyp27a1 (B), and Cyp8b1 
(C)) were determined. Total bile acid levels in mouse gallbladder bile (D) and plasma (E). Cont, Control 




4.5 IMPACT OF ETHANOL CONSUMPTION ON ILEAL EXPRESSION AND 
CIRCULATING LEVELS OF FGF15 (HEPATIC FXR/SHP PATHWAY AND 
FXR/FGF15/FGFR4 PATHWAY) 
 
The expression of the Fgf15, Fxr and Diet1 genes in ileum was subsequently controlled. Here 
a significant induction of the Fgf15 gene expression in WT mice upon ethanol uptake was 
determined (p=0.032), but not in the KO group (Figure 10D). However the circulating FGF15 
plasma levels were similar between the groups (Figure 11). The ileal Fxr gene expression was 




(Figure 10E). No significant differences were observed in the expression of Diet 1, which has 
been suggested to modulate bile acid and lipid levels through the FGF15/19 enterohepatic 
signaling axis (Figure 10F). 
To further clarify the molecular pathway of Cyp7a1 repression upon ethanol challenge, we 
analyzed the hepatic expression level of the nuclear receptor FXR, which inhibits Cyp7a1 and 
Cyp8b1 gene transcription by inducing the nuclear receptor SHP. However, no significant 
difference in expression levels of hepatic Fxr and Shp was observed among groups (Figure 
10A-10B) suggesting that the repression of Cyp7a1 gene expression was independent of the 
hepatic FXR/SHP pathway in our model. 
Perhaps the best known mechanism of repression of Cyp7a1 is based on the activation of FXR 
in ileum, which induces the intestinal hormone FGF15. FGF15 in turn induces FGFR4 signaling 
in the hepatocytes. In the WT mouse group a significant upregulation of ileal Fgf15 (p=0.032) 
and Fxr gene expression (p=0.018) could be ascertained upon ethanol intake. This effect was 
howbeit absent in the KO group. Interestingly we could not detect any differences in the 
circulating levels of FGF15 between the groups. The result seemed to be thus inconsistent. 
We therefore proceeded to evaluation of the expression levels of Diet1/Malrd1 gene in ileum, 
which is supported to have an impact on the FGF15 secretion from its site of ileal production 
into the portal circulation (69). The expression levels of Diet1 were correlated with the 
expression pattern of Fgf15 indeed. The higher levels were detected in WT mice after the 
ethanol consumption. Despite this correlation there was absence of statistically significant 
differences between the mouse subgroups, as far as Diet1, Fgfr4 and its co-receptor β-Klotho 
are concerned. Precisely this observation leads to the assumption, that the suppressive impact 
of FGF21 on CYP7A1 and consequently the rate limiting step of the bile acids biosynthesis 
could be exerted through a direct action of FGF21 and not definitely through a synergistic effect 
with FGF15/19. This independent action of FGF21 is presumably more marked and axial in 








Figure 10: Relative quantification of mRNA levels of hepatic/ileal genes that play a role in transcriptional 
regulation of the Cyp7a1 gene. Transcriptional levels of hepatic Fxr (A), Shp (B) and Fgfr4 (C) and ileal 
Fgf15 (D), Fxr (E) and Fgfr4 (F) were determined. Cont, Control diet; EtOH, Ethanol diet; KO, Abcb4 
knockout mice; WT, C57BL/6J wild-type mice. p<0.05 was considered significant. 
 
Figure 11: Plasma FGF15 levels in mice quantified by ELISA. Cont, Control diet; EtOH, Ethanol diet; 





4.6 STUDIES IN HUMAN COHORTS 
 
Similar pathophysiological processes concerning the endocrine fibroblast growth factors and 
their impact on bile acids metabolism upon ethanol consumption in humans were 
hypothesized. In order to verify if our findings could be translated  to human cohorts, we 
objectified the impact  of ethanol intake on FGF21 and bile acid biosynthesis by determining 
FGF21, FGF19 (the human orthologue of FGF15 in mice), 7α-hydroxycholesterol (7αOHC) 
and  27-hydroxycholesterol (27OHC) levels in blood in two cohorts of human subjects. The 
cohort of healthy volunteers did not have any known preexisting liver disease. The second 
cohort consisted of patients with previously diagnosed alcoholic liver disease and admitted 
ongoing ethanol consumption, which was objectified via measurement of serum CDT. For the 
objectification and quantification of alcohol intake and liver damage, biochemical markers in 
serum were determined. CDT, ALT and AST levels were found to be significantly elevated in 
ALD patients with ongoing alcohol ingestion (p<0.001, p=0.004 and p<0.001, respectively) 
(Figure 12). 
Consistent with the results in mice, a significant (p<0.001)  upregulation of FGF21 in the cohort 
with ongoing ethanol consumption was observed, furthermore supporting our conclusion that 
the ethanol induced elevation in circulating levels of FGF21 remains preserved, even in the 
frame of a preexisting liver pathology. (Figure 13A). There were no significant differences in 
the plasma FGF19 levels between the groups, a result which is in line with mouse plasma 
FGF15 results (Figure 13B). 
 
Figure 12: Plasma CDT (A), ALT (B) and AST (C) levels in humans. ALD, alcoholic liver disease; ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; CDT, carbohydrate-deficient transferrin. 






Figure 13: Plasma FGF21 (A) and FGF19 (B) levels in human plasma samples quantified by ELISA. All 
data are shown as means ± SE. p<0.05 was considered significant. 
 
To further clarify a potential influence of ethanol consumption on the expression of CYP7A1 
and CYP27A1 genes in humans, we evaluated the serum concentration of the specific 
metabolites 7a-hydroxycholesterol (7aOHC) and 27-hydroxycholesterol (27OHC). 7aOHC is 
suggested to be a biomarker for the 7a-hydroxylase activity, and 27-hydroxycholesterol  a 
biomarker for CYP27A1 activity in humans respectively. In line with our observations in mice, 
a significant suppression of 7aOHC was denoted in patients with alcoholic liver disease (p= 
0.02) (Figure 14A). Unexpectedly however, the levels of 27OHC were similar between groups 
(Figure 14B). 
  
Figure 14: Serum levels of 7αOHC (A) and 27OHC (B) in humans detected by isotope dilution GC-mass 




During the basic screening of the recruited humans, serum TBA were found to be significantly 
elevated (p=0.01) despite a non-significant reduction of total cholesterol levels in the group of 
patients with alcoholic liver disease (Figure 15). In summary, these data suggest a significant 
elevation in TBA and FGF21 levels in plasma of ALD patients in the absence of significant 
changes in circulating FGF19 levels upon ongoing ethanol consumption.  
 
Figure 15: Human serum total bile acid (A), total cholesterol (B), and triglyceride (C) levels. p<0.05 was 
considered significant. 
 
4.7 EFFECT OF EXOGENOUS HUMAN RECOMBINANT FGF21 ON THE 
EXPRESSION OF CYP7A1 IN PRIMARY MOUSE HEPATOCYTES 
 
We extended our experiments in order to collect more data supporting a direct suppressive 
effect of FGF21 in the biosynthesis of the bile acids. We applied human recombinant FGF21 
to murinal hepatocytes in order to dissect its effect on the rate limiting step of BA biosynthesis.  
In murinal primary hepatocytes, the application of rhFGF21 suppressed the expression of 
Cyp7a1 dose-dependently. There was initially observed that the levels of Cyp7a1 were 
marginally reduced after application of lower rhFGF21 doses (0.1 and 0.25 µg/ml). After 
application of 0.5 µg/ml and 1 µg/ml doses a marked suppression relative to controls took 
place, by 25% and 70% respectively (Figure 16A). To clarify whether these alterations were 
induced directly or indirectly, expression levels of Fxr and Shp were determined. There were 
observed no significant changes for both. (Figure 16B-16C). Furthermore, there were no 
significant differences in gene expression of hepatic Fgf21, Fgfr1 and Klb ascertained after the 
exogenous administration of  FGF21 (Figure 16D, 16E and 16F). Consistent with the previously 
mentioned in vivo findings of the current study, these results enhance the existence of a direct 
impact of exogenously administered rhFGF21 on Cyp7a1 gene suppression, which acts 






Figure 16: Effect of rhFGF21 on primary mouse hepatocytes. Transcriptional levels of the Cyp7a1 (A), 
Fxr (B), Shp (C), Fgf21 (D), Fgfr1 (E) and Klb (F) genes in primary mouse hepatocytes treated with 
rhFGF21 (0.1-1 µg/ml) or vehicle (white) for 24 h. All data represent -fold change compared to control 
hepatocytes (mean ± SE, n=3). p<0.05 was considered significant. 
 
4.8 HISTOLOGICAL ASSESSMENT OF MICE LIVER 
 
The histological evaluation of the murinal liver tissues revealed signs of hepatic inflammation 
with infiltration with numerous inflammatory cells detected by H&E staining in mice after 
ethanol intake regardless of genotype (Figure 17A). The latter indicates the existence of 
increased hepatic steatosis. Sirius red staining of liver sections pointed to an aggravation of 





Figure 17: Assessment of liver fibrosis and inflammation. Hematoxylin and eosin staining of liver 
sections with 20X magnification (A) and Sirius Red stained liver sections with 5X magnification (B). Black 
arrows show infiltrating inflammatory cells. Each scale bar is 100 μm. EtOH, Ethanol diet; KO, Abcb4 

























The conducted study aimed to offer a multidimensional vision over the impact of alcohol 
ingestion and alcoholic liver disease on the endocrine fibroblast growth factors, FGF21 and 
FGF15/19, and vice versa. A further purpose was to clarify the role of FGF21 in bile acid 
metabolism, which could have pharmacological interest. In our knowledge there are only 
sparse data about the influence of alcohol on FGF15/19. Despite the previously observed 
intense upregulation of FGF21 after binge ethanol intake (27,128), the impact of chronic 
alcohol abuse or an underlying liver pathology has not yet been well studied. In this setting, 
we pursued to delineate the crosstalk between FGF15/19, FGF21 and bile acid metabolism, 
elucidate a part of their biological function in the frame of alcohol intake and figure out any 
alterations caused by a preexisting cholestatic liver pathology.  
The results of the present study support a marked upregulation of hepatic and circulating 
FGF21 levels in both humans and rodents after ethanol ingestion. The significant upregulation 
was preserved in patients with underlying ALD as well as in Abcb4 KO mice. This implies that 
ethanol induced upregulation of hepatic and serum FGF21 levels remains intact even in the 
context of a preexisting liver pathology. The in vivo studies pointed furthermore to a significant 
downregulation of hepatic Cyp7a1 expression after chronic plus binge ethanol intake. The in 
vitro studies supported this suppression to take place in a dose-dependent manner.  Moreover, 
since there were not any changes in expression levels of hepatic Fxr, Shp or plasma FGF15/19 
levels after ethanol challenge, we propose that alcohol induced FGF21 has a direct effect on 
Cyp7a1 downregulation, which is independent of FXR-SHP or FGF15/FGFR4 pathways.  Τhe 
upregulation of FGF21 during an emerging hepatocellular damage could be seen as  a reactive 
mechanism for the attenuation and diminished progression of the metabolic and oxidative 
alterations, leading firstly to steatosis and ultimately to fibrosis and cirrhosis (60). However, the 
impact of FGF21 on bile acids synthesis and metabolism has been shown to be controversial. 
FGF21 has been suggested recently to act as a negative regulator in the biosynthesis of bile 
acids and interestingly also in an FGF15/19 independent manner (17). The findings of the cited 
study indicated a complicated mechanism of action, which is dependent on the administered 
doses of FGF21 and the duration of administration. There were furthermore slight differences 
in the biological actions of recombinant human FGF21 and endogenous FGF21. These data 
suggest an existing role of FGF21 in bile acids metabolism, which could be influenced through 
not yet fully elucidated parameters. In another recent study, a completely opposite action of 
FGF21 has been supported, with direct antagonization of the effect of FGF15/19 on the down 




observed with long-term administration of high doses of FGF21, supporting the study 
mentioned above (17). On the contrary, an expected downregulation of Cyp7a1 was observed 
following acute FGF21 administration in rodents with unchanged FGF15 levels, which 
consistently supports an FGF21 induced suppression of bile acids synthesis independent of 
FGF15/19 (17). These data are supportive for the existence of a feedback loop between 
CYP7A1 and FGF21, with still unclarified regulating biologic factors, presumably FGF15/19 
independent. 
In both WT and KO mice, a statistically significant elevation of serum transaminases was 
ascertained after chronic plus binge ethanol ingestion, following the elevation of serum ethanol 
values, which is indicative of the biochemical impact of alcohol ingestion on liver parenchyma 
(induction of an acute or acute on chronic liver injury respectively). The evaluation of hepatic 
expression and serum levels of FGF21 revealed a statistically significant upregulation in KO 
mice as well as WT mice, showing preserved effect in the frame of a preexisting liver pathology. 
Of course the elevated serum level of an endocrine factor could mean either a reactive 
upregulation for boosted biological effect or presence of a resistance state. The latter has been 
presumed for FGF21 in obesity and also diabetes (38) and should not be underestimated, 
taking into account the complex interaction of FGF21 with its receptor and the necessity of an 
obligate co - receptor for the downstream signaling cascade. What is compelling in the present 
study is the fact that the FGF21 elevation was not due to the liver pathology but the alcohol 
itself. In addition, there was no significant difference between FGF21 levels of WT and KO 
mice at the baseline, indicating that the liver disease itself did not cause a change in hepatic 
Fgf21 expression levels.  
We have additionally examined the impact of chronic plus binge ethanol intake on FGF15, 
which is an ileal produced enterokine. Similar to FGF21 results we could not detect any base 
line differences between WT and KO mice, a fact suggesting an irrelevant impact of the 
preexisting liver disease itself.  Upon ethanol challenge we denoted a significant upregulation 
of ileal expression of Fgf15 mRNA in the WT group but not in the Abcb4 KO mice. Given the 
previously supported role of FGF15 in the downregulation of bile acids synthesis, this 
suppression could impede the progression of fatty liver disease and steatohepatitis. Thus, the 
observed upregulation of FGF15 could have a hepatoprotective effect, which is presumably 
not preserved in the frame of a preexisting cholestatic liver pathology. This could further imply, 
that on the physical course of the different stages of alcoholic liver disease, a progressive 
deprivation of the FGF15 mediated feedback control in the bile acids synthesis takes place, an 
event that could in turn accelerate the aggravation of the hepatic disease. However, in this 




challenge between mice groups, a fact suggesting a rather local action of it in the intestine-
liver axis, at least in our experimental setting. 
There seems to be a bidirectional relationship between bile acids synthesis and alcoholic liver 
disease, as the ethanol consumption itself has an impact on BA synthesis in liver. This action 
has been suggested to be predominantly mediated by the farnesoid X receptor (78). The 
increased BA synthesis has been reported to emerge through induction of Cyp7a1 and Cyp8b1 
transcription with inhibition of Fgfr4 expression, which is suggested to be a transcription 
inhibitor of Cyp7a1 (157,158). Since the expression levels of FGFR4 remained unchanged in 
our study, these steps seem to be influenced upon ethanol intake in the present experimental 
setting. This could albeit presumably imply a counteraction of the inhibitory effect of ethanol 
itself on FGFR4. The crucial factor appears to be the elevation of hepatic and circulating levels 
of FGF21. Following this elevation, a suppression of Cyp7a1 and Cyp8b1 takes place. 
Furthermore, it has previously been described that the ethanol-induced upregulation of Cyp7a1 
and Cyp8b1 is enorchestrated by activation of cAMP responsive element-binding protein 
(CREBH) through ethanol induced stimulation of the cannabinoid receptor type 1 (CB1R). 
CREBH is besides considered as a central metabolic regulator and these data support the 
consideration of the alterations in BA synthesis as part of a metabolic shift caused by alcohol 
intake (16). The altered conjugation of bile acids, which directly influences their toxicity, is 
induced via analogous changes in the necessary metabolic enzymes. As expected, the 
existing evidence supports the reduction in the levels of bile acid CoA: amino acid N 
acyltransferase (BAAT) and the upregulation of bile acid CoA synthetase (BACS) after alcohol 
intake. The first catalyzes the taurine conjugation and the latter the glycine conjugation (158). 
The elevated reabsorption of bile acids in the enterohepatic circulation following the ethanol 
consumption is mirrored in the expression of liver and ileal transporters, which lead to both 
elevated excretion and reabsorption. The liver transporters, which are reported to be 
upregulated include the bile salt export pump (BSEP), organic solute transporter α/β (OST α/β) 
and multidrug resistance protein 4 (MRP4), all of them increasing the BA efflux. The BA 
reuptake transporters, such as the sodium taurocholate cotransporting polypeptide (NTCP), 
have been found downregulated. The upregulated ileal transporters include the apical sodium 
dependent bile acid transporter (ASBT) and organic solute transporter β (OST β)(157,158). 
The FGF21-CREBH axis could bear in the light of the above data a pivotal hepatoprotective 
role under conditions of chronic or binge alcohol intake. 
At least a part of the effects of ethanol consumption on the bile acid synthesis was proposed 
to be mediated via an ethanol induced down regulation of the farnesoid X receptor, which is 
suggested to suppress the expression of CYP7A1 and CYP8B1 and induce the expression of 




to be a reduced acetylation of the receptor, mediated perhaps through downregulation of 
Sirtuin 1 (SIRT1), which is a histone deacetylase dependent on nicotinamide adenine 
dinucleotide (NAD+) and on the other side activation of acetyltransferase p300 (95,157,162). 
In this way, it is proved one more time that the ethanol induced alterations in the 
oxidative/reductive potential in the hepatocyte can trigger multiple structural and functional 
changes that have altogether a negative impact on its function. The indication of the negative 
role of the ethanol mediated downregulation of FXR leads to the testing of FXR agonists as 
pharmacological agents for amelioration of the alcoholic liver disease, with two of them (WAY 
and 6a-rthyl-chenodeoxycholic acid-6ECDCA) showing an improving effect on liver steatosis 
(73,157). However, there are also converse findings reported. For instance, FXR has been 
suggested to deconjugate cAMP response element binding Protein (CREB) from its co-
activator CREB regulated transcription co-activator 2 (CRTC2), inhibiting indirectly the 
autophagy via decreased expression of associated genes (121). The precise mechanism has 
not yet been fully elucidated as other contributing factors, as the AKT, are influenced by ethanol 
consumption as well (79). Another receptor inducing autophagy seems to be the PPARa, 
whose activation occurs under different circumstances from those needed for stimulation of 
FXR. The latter is rather activated in the fed phase and after the return of bile acids into the 
liver via the enterohepatic circulation, whereas the main stimulus for PPARa is the production 
of free fatty acids during starvation (14,33,49,63,77,144). PPARa and FXR are claimed to have 
opposite effects on the transcription of autophagy related genes (70), a fact that endorses a 
stimulating for the autophagy role of PPARa and an inhibiting role of FXR. The above 
mentioned role of FXR is not endorsed by our findings, where no significant alteration of the 
expression of this receptor were observed between the mice genotypes neither at baseline nor 
after alcohol ingestion. On the contrary, the anticipated upregulation of PPARa was indeed 
ascertained. The notion that a procedure, such crucial for the progression of alcoholic liver 
disease as the autophagy, is regulated from known receptors, which could pose 
pharmacological targets, is compelling, but the existing data are inconsistent and further basic 
and clinical research is yet required in this field. 
The present study ascertained a downregulation of the expression of Cyp7a1, which encodes 
the rate limiting enzyme of the biosynthetic procedure of BA in both ethanol challenged WT 
and  Abcb4 KO mice. The observed suppression reached the limit of statistical significance in 
both mouse groups, although in the group with the preexisting liver damage the expression of 
Cyp7a1 was reduced as compared with the WT group at the baseline. This is a further 
reflection that different causes of a hepatic pathology induce a mechanism that suppresses 
the synthesis of bile acids, in order to avoid hepatotoxic effect. The induction of ileal FGF15 




of the rate limiting enzyme of the BA synthesis in the latter group is presumably not mediated 
through FGF15. Taking into account that the FGF21 upregulation was consistent in both 
mouse groups, we can presume that the observed downregulation tendency in the KO group 
occurs due to the direct action of FGF21, without the cooperative action of these two endocrine 
fibroblast growth factors. This leads furthermore to the assumption that, in the course of a liver 
disease, the capability to reduction of hepatotoxicity of the BA through quantitative and 
qualitative alterations in their pool can progressively be abolished. Further research is required 
in order to clarify if there is a causative correlation between these two processes and a linear 
association between stage of liver disease and reduction in feedback control of BA synthesis. 
We also observed the impact of ethanol intake on Cyp27a1, which is a gene encoding the 
enzyme sterol-27-hydroxylase, which is located in diverse tissues and responsible for many 
reactions, but undertakes a major role in the bile acid synthesis. It exhibits a cholesterol 27-
hydroxylase and vitamin D3-hydroxylase activity and its intracellular localization is in the 
mitochondria. Due to its role in the biosynthetic pathway of BA it can be used as a biomarker 
of extrahepatic cholestasis (13) and as such was entailed in our experimental study. As found 
in expression levels of Cyp7a1 as well, we ascertained a statistically significant suppression 
of Cyp27a1 in WT mice. A suppression of Cyp27a1 in the KO mice challenged with ethanol 
was found only when compared to WT-Cont mice. In the control diet challenged KO mice, 
there was a trend of reduction as well, although the downregulating trend in this group was not 
statistically significant. These data support further the decline of the capability for controlling 
the BA biosynthesis in the frame of previous liver damage at one further step and could be 
associated with the previously mentioned importance of FGF15 in the regulation of the whole 
feedback loop. The latter has been already documented in the literature (60). 
CYP8B1 (Cytochrome P450, family 8, subfamily B, polypeptide 1), also named sterol 12-alpha-
hydroxylase, which is an endoplasmic reticulum membrane located enzyme and catalyzes the 
conversion of 7-alpha-hydroxy-4-cholesten-3-one into 7-alpha,12-alpha-dihydroxy-4-
cholesten-3-one has also been investigated in the current study. The relevance of this catalytic 
reaction lies in the regulation of the relative amounts in the BA pool of the two primary bile 
acids, namely the cholic and chenodeoxycholic acid. This monooxygenase is further relevant 
in many reactions controlling drug metabolism and synthesis of cholesterol, steroids and other 
lipids and can influence the solubility of cholesterol. Although there are published data 
indicating that CYP8B1 can aggravate dyslipidemia (101), the exact pathophysiological role of 
this enzyme in cholestasis and lipid regulation has not yet been fully elucidated. Our findings 
showed an immersing suppression of Cyp8b1 after ethanol intake only in the KO group 
emphasizing the importance of an established chronic liver injury in the presence of an acute 




In addition, interestingly, no significant effect of alcohol challenge on hepatic mRNA levels of 
Fgfr1 and Fgfr4 was observed. Although it needs further investigation, this fact suggests that 
the expression levels of these receptors could be enough for an effective binding of the 
endocrine fibroblast growth factors and a subsequent upregulation may not be needed. In 
addition, similar to Cyp8b1, although it was not statistically significant, a decrease in 
expression levels of hepatic Klb has been observed only in the KO-EtOH mice group, pointing 
to the modulating effect of pre-injured liver in ACLI. Although several studies have showed the 
role of KLB in tumorigenesis (106,161), these results are controversial and its exact role in 
ACLI needs further investigations. We could furthermore discern a significant impact on the 
expression of ileal Fxr only in the WT-EtOH mice group, in which ileal Fgf15 expression levels 
were significantly upregulated. The induction of ileal Fgf15 gene expression could be 
suggested to take place following the activation of FXR in the frame of an FXR-FGF15/19 
enterohepatic pathway. However, the lack of significant changes of ileal Fxr and Fgf15 
expression levels and plasma FGF15 levels in the KO-EtOH mouse group suggest that 
downregulation of hepatic Cyp7a1 is independent of FGF15 in our ACLI model.  
The small heterodimer partner (SHP) or else NR0B2 (nuclear receptor subfamily 0, group B, 
member 2) is a member of the nuclear receptor family of intracellular transcription factors (68). 
Although classified as a nuclear receptor is missing a DNA binding domain and has a variety 
of interacting partners, a fact that indicates a multidimensional potential, regulating drug, 
glucose, bile acids, cholesterol and triglycerides metabolism (15). As far as the BA metabolism 
is concerned, SHP is considered to inhibit the conversion of cholesterol to bile acids, 
undertaking hence a potential hepatoprotective role preventing excessive cholestasis (15,100). 
Previously published data point to an essential role for SHP signaling in ethanol catabolism, 
as Shp -/- mice displayed enhanced ethanol catabolism and clearance and reduced ethanol 
induced hepatic inflammation compared with their wild type counterparts (100). Consequently, 
the suppression of SHP could be part of a favorable hepatoprotective pathomechanism.  
However, in this study, no significant difference in expression levels of hepatic Fxr and Shp 
was observed between groups suggesting that repression of Cyp7a1 gene expression was 
also independent of FXR/SHP pathway in our model.  
The sterol regulatory element-binding transcription factor 1 (SREBF1) or sterol regulatory 
element-binding protein 1 (SREBP-1) is another key regulator of lipids metabolism in liver. It is 
related with the signaling pathway of PPARa and circadian rhythm related genes (123). Recent 
data indicate its association with multiple further cellular signals, implicating SREBF1 in 
diabetes mellitus type 2, malignancies, immune response, neuroprotection and autophagy 
(123). Its emerging role in lipogenesis, autophagy and inflammation and association with fatty 




during ethanol consumption. Since there was no significant difference in hepatic expression 
levels of Srebf1 in our study, this result suggests that the transcription factor SREBF1 does 
not have a direct impact on FGF21 upregulation in our ACLI model.  However, our results 
showed statistically significant upregulation of hepatic Ppara expression levels after ethanol 
challenge in both WT and KO mice showing no difference between genotypes. These results 
suggest that PPARa, but not the transcription factor SREBF1, may have a direct impact on 
FGF21 upregulation. Indeed, there is a linear positive correlation between PPARa and FGF21 
demonstrated both in humans and mice (76). It is thereupon expected that we found 
concomitantly with the upregulation of hepatic and circulating FGF21 upon ethanol challenge, 
a statistically significant elevation of PPARa as well. The protective role of PPARα in alcoholic 
liver disease was suggested from Nakajima et al. already since 2004 (91). Later FGF21 was 
proposed as the mediator of the metabolic favorable function of PPARα both in alcoholic and 
metabolic associated liver disease and our study results support the suggested correlation. 
The impact of PPARa on FGF15 and the FXR-FGF15 axis is more controversial. The existence 
of an inverse correlation has previously been supported (148). This presumably inverse 
correlation between PPARa and FGF15/19 is further reinforced from a demonstrated 
downregulation of FGF19 after treatment with PPARa-agonists (fenofibrat) in patients with 
Type 2 Diabetes Mellitus (88).  
To investigate the effect of alcohol on FGF21 signaling pathways, hepatic mRNA levels of the 
Mtor (downstream mediator mTOR), which is a member of the phosphatidylinositol 3 –kinase-
related family of protein kinases, was also investigated in this study. There are sparse data 
proposing a suppression in mTOR signaling pathway in ethanol exposed hepatocytes (139). 
Additionally, a suppressed mTORC1 signaling has been suggested to ameliorate fat 
accumulation and inflammation in alcoholic liver disease and to be associated with improved 
prognosis (34,165). It has also been supported that the mTOR signaling is upregulated in 
hepatocellular carcinoma (34), a fact that has pharmacological extensions. In our study, a slight 
tendency of downregulation of Mtor in mice challenged with ethanol was observed. However, 
since there was no statistically significant changes between mice groups, our results denote 
that the downstream signal transduction of FGF21 is possibly not mediated through an mTOR 
pathway, which was previously reported to have a regulatory role in the FGF21 signaling 
network (85).  
Significant upregulation of ileal Fgf15 and Fxr gene expressions in the WT mice were observed 
upon ethanol uptake but not in the KO group. However, interestingly, the circulating FGF15 
plasma levels did not differ between groups. To clarify this incompatible result, we also 
measured the expression levels of Diet1/Malrd1 gene in ileum, which has been shown to play 




feedback control loop of bile acid synthesis (152). DIET1 is expressed on the epithelial cells of 
intestine (and on cells of kidney cortex), but not in hepatocytes. DIET1 deficiency is suggested 
to inhibit the production of ileal FGF15/19 and thus impair the intact function of the 
enterohepatic feedback loop (152). Conversely, the increase in DIET1 levels enhances the 
FGF15/19 production and subsequently suppresses Cyp7a1 (152). The influence of DIET1 on 
FGF15/19 emerges through a post-transcriptional mechanism, possibly through an 
intracellular mechanical interaction (152). In our knowledge there are no present data for the 
impact of alcohol intake on DIET1 expression. In the present experiments, although the 
expression levels of Diet1 showed similarity with the expression pattern of Fgf15, with higher 
levels in the WT mice challenged with ethanol, we did not observe any significant difference in 
the basal levels of DIET1 between mice groups and upon ethanol challenge. Our results do 
not support a significant impact of alcohol intake on a DIET1 mediated regulation of FGF15 in 
both WT or Abcb4 deficient mice. 
We considered the detected upregulation of FGF21 upon ethanol challenge in both WT and 
KO mice and its potential correlation with the suppression of the biosynthesis of bile acids via 
direct action on the rate limiting step of their biosynthetic cascade the most compelling finding. 
In addition, our results did not support FXR-SHP or FGF15/FGFR4 pathways dependent 
downregulation of Cyp7a1. Therefore, to investigate the direct effect of FGF21 on hepatic 
Cyp7a1 mRNA suppression, cell culture studies were performed by using mouse primary 
hepatocytes. The results showed that rhFGF21 decreased Cyp7a1 expression levels in a dose 
dependent manner. This outcome strongly supports the direct effect of FGF21 on the BA 
biosynthesis, independently of FGF15/19.  
Previously well-designed studies had already proved a robust upregulation of FGF21 upon 
alcohol ingestion in healthy volunteers and proposed a negative feedback loop in the liver brain 
axis that leads to suppression of excessive alcohol consumption. It is further suggested that 
this loop could be the evolutionary remnant of an analogous mechanism for the limitation of 
consumption of fermentated carbohydrates in our ancestors (154). In our study we also 
investigate if this potential hepatoprotective mechanism remains intact even in the presence 
of a preexisting liver disease. Therefore, we also examined the effect of alcohol intake on 
FGF21, FGF19, and bile acid regulation in human subjects with alcoholic liver cirrhosis and 
admitted ongoing ethanol abuse compared to healthy controls. We could not submit the 
patients to a quantifiable exogenous alcohol application as this would be unethical. Therefore, 
we objectified the admitted consumption via detection of alcohol metabolites (carbohydrate-
deficient transferrin - CDT). In our enrolled ALD patients the CDT levels were elevated in a 
statistically significant level, as compared with a control group of healthy subjects, who denied 




patients comparatively to the control cohort and we identified alterations common in ALD. The 
serum transaminases were significantly elevated in the ALD cohort, as were the serum total 
bile acids, a fact that indicates a present dysregulation of bile acids metabolism. On the 
contrary, serum total cholesterol was detected significantly reduced compared to the control 
group. This is consistent with previous findings revealing a significant reduction in levels of 
total cholesterol in patients with alcoholic liver cirrhosis in comparison to control groups and 
coherent with the expected pathophysiological impact of ethanol on cholesterol metabolism 
(22). 
In accordance with the current in vivo data, an upregulation of circulating FGF21 in the cohort 
of patients with alcoholic liver disease was confirmed compared to the healthy control group. 
Although the hepatic expression levels of FGF21 has not been examined in the human 
subjects, previous data consistently support that the liver production of this hepatokine 
conferes the major part of the plasma levels. Our data support that the beforehand regarded 
robust upregulation of FGF21 in healthy subjects upon ethanol challenge remains preserved 
even in the setting of an existing liver damage and the established hepatocellular injury seems 
not to significantly influence the capability of upregulated FGF21 production. In our knowledge 
there are sparse hitherto published data for the influence of alcohol use disorder and alcoholic 
liver disease on FGF21 in humans. However, we cannot definitely conclude if the elevated 
serum FGF21 levels are attributable to the induction of a reactive protective pathomechanism 
or imply a resistance state, as in patients with diabetes and obesity. Independently from that, 
our findings suggest that exogenous FGF21 application could be studied as a potential 
pharmacological treatment for the amelioration of chronic and acute liver damage of alcoholic 
etiology. 
In accordance with our findings in mice, the circulating levels of FGF19 in the patients with 
alcoholic liver disease and ongoing ethanol consumption did not significantly differ, although a 
slight trend to upregulation could be detected. This finding suggests that a considerable 
endocrine action of FGF19 is not induced in humans with alcoholic liver disease after ongoing 
ethanol abuse. At this point must howbeit be noted that the main expression site of FGF19 is 
the small intestine and that FGF19 does not exclusively act in an endocrine manner, but as a 
paracrine factor in the liver-intestine axis as well. Hereby can we though refer to the murinal 
findings, where an intestinal upregulation of FGF15 in the cholestatic liver after alcohol intake 
could not be ascertained neither. As a whole, we can reliably assume that the main endocrine 
fibroblast growth factor affected by alcohol intake in humans with previously established liver 
disease is FGF21. We can consequently suggest that the further observed alterations, 





After the recognition of the ethanol induced changes in the levels of FGF21 and FGF19 in the 
frame of ongoing alcohol consumption by preexisting alcoholic liver disease, we extended our 
study in order to clarify the ensuing consequences for the biosynthesis and metabolism of bile 
acids. To this purpose, in order to translate our findings to humans, we evaluated the effects 
of alcohol consumption on the oxysterols 7a-hydroxycholesterol (7aOHC) and 27-
hydroxycholesterol (27OHC) levels in serum samples of both human groups. Since CYP7A1 
catalyzes the conversion of cholesterol to 7a - OH cholesterol, which is a precursor of bile 
acids in the classic pathway, its serum levels represent an estimation of the CYP7A1 activity 
and consequently the saturation of the rate limiting step in the BA biosynthesis. The serum 
levels of 7a - OH cholesterol were significantly suppressed in the ALD group with continuing 
alcohol intake compared to healthy controls, which was in line with our in vivo findings. On the 
contrary, 27OH cholesterol levels, which is minor precursor of the bile acids synthesis, did not 
show significant differences between the groups.  The latter finding is very interesting, because 
it correlates with the lack of statistically significant suppression of CYP27A1 in the Abcb4 
knockout mice in our murinal experiments. This could imply a deficit in the ability of control of 
this step of BA synthesis in the frame of a preexisting liver pathology. It could furthermore be 
associated with the fact, that 27-OH cholesterol has multiple functions, not only in BA 
metabolism, but endocrine as well. It can for instance act as a selective estrogen receptor 
modulator and thus is part of more than one feedback control loops (80). In summary, the 
findings of the present study point to a correlation between alcohol induced FGF21 and 
suppression of the rate limiting enzyme in BA synthesis by an unknown FGF15-independent 

















The main finding of the present experimental study is the suppression of the bile acid synthesis 
rate limiting enzyme CYP7A1 by chronic plus binge alcohol-induced FGF21 in an FGF15/19-
independent pathway, due to the lack of changes in neither expression levels of hepatic Fxr 
and Shp nor plasma FGF15/19 concentrations after ethanol challenge. Our results suggest a 
direct effect of FGF21 on Cyp7a1 suppression, which is supported by our in vitro studies. 
Therefore, our findings are in line with studies supporting a previously unidentified role of 
FGF21 as a negative regulator of bile acid synthesis (79). In addition, the results support the 
recent notion proposing the Cyp7a1 suppression effect of FGF21 to be mediated 
independently of FGF15/19 (79, Figure 18). Moreover, in accordance with the in vivo results, 
our translational human studies showed a significant FGF21 upregulation and a significant 
reduction of serum 7aOHC concentrations in patients with alcoholic liver disease and ongoing 
ethanol consumption but unchanged plasma FGF19 levels. However, in the current study, the 






Figure 18: Suggested alternative pathway for bile acid synthesis regulation upon ethanol challenge. 
Dashed lines for induction and repression are based on literature data, whereas straight lines show the 
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